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People with Chronic Obstructive Pulmonary Disease (COPD) have high rates of accidental falls.  
Increased gait variability and poor balance control are known as risk factors for accidental falls in this 
population.  Exertional walking tasks are used in clinical assessments, however changes in gait 
variability and balance control during exertional walking assessments are not well researched.  This 
study aims to assess changes in gait variability and balance control during and immediately after 
walking assessments, and the relationship these falls risk factors have with exertion. 
 
Methods 
Participants recruited from a pulmonary rehabilitation program performed two Six-Minute Walk 
Tests (6MWT) and two Incremental Shuttle Walk Tests (ISWT) one week apart, in a randomised 
order.  Gait variability was measured using a gait sensor mat during the walk tests, and balance 
control was measured using Functional Reach Test (FR) before and after each walking test.  The 
results were compared using a paired t-test.  Concurrently, measures of exertion Rate of Perceived 
Exertion (RPE), Respiratory Rate (RR), Heart Rate (HR), Peripheral Oxygen Saturation (SpO2), and End-
Tidal Carbon Dioxide (ETCO2) were collected during each walking test.  
 
Results 
Twenty people (17 females, 3 males), aged 71 (±8) years, with Forced Expiratory Volume in one 
second (FEV1) percent 64 (±18%) of predicted, and Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) rank 2.2 (±0.75) attended on two occasions.  There was no statistically significant 
change in any of the measures of gait variability analysed from start to end-test in either the 6MWT 
or the ISWT, despite significant statistical change in RPE (p= .002, p= .007, respectively), HR (p= .010, 
0.009, respectively), and SpO2 (p= .004, p= .034, respectively) for both walk tests, and RR (p= .006) in 
Abstract 
Page | 2  
 
the 6MWT.  Stance time standard deviation had a small but statistically significant inverse 
association with HR (r= - .143, p= .016) in the 6MWT and a positive association with RPE (r= .133, p= 
.049) in the ISWT. There were no other statistically significant associations with measures of 
exertion.  There was no statistically significant difference in FR between pre or post reach in the 
6MWT (30.08 ±6.15, 29.95 ±5.08 cm, respectively; p= .860), or in the ISWT (30.88 ±5.95 pre-test and 
30.23 ±5.51cm post-test, p= .463).   
 
Conclusions 
There was no increase in gait variability despite participants reaching maximum levels of exertion 
and balance control, as measured by FR test did not change immediately after participating in the 
walk tests.  These results indicate that participating in the 6MWT and ISWT does not degrade gait 
variability from baseline levels of exertion in a community-dwelling COPD cohort and supports the 








CHAPTER 1 Introduction 
Chapter one introduces gait variability in Chronic Obstructive Pulmonary Disease (COPD) as a risk 
factor for accidental falls and describes how gait variability in relation to level of exertion is under 
researched despite its clinical importance.   
 
CHAPTER 2 Literature review 
This chapter reviews the literature relating to the magnitude of accidental falls in COPD, develops the 
need to determine risk of falling in relation to elevated exertion and provides a rational for using gait 
variability as an assessment tool for falls risk. 
 
CHAPTER 3 Methods 
The Methods chapter contains the pilot study procedure for the study ‘Changes in gait variability and 
balance control during exertional walking in adults with chronic obstructive pulmonary disease’. 
 
CHAPTER 4 Results 
Chapter 4 contains the demographic analysis of the pilot study participants and presents results 
relating to the study aims.   
CHAPTER 5 Discussion  
This chapter discusses how the pilot study conducted addresses the study aims, compares findings 
with current literature, critiques the study protocol and ends with the clinical implications of this 
research and recommendations for future research in this area.   
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Introduction 
Overview of the problem 
Poor gait regularity, reduced balance control, and falls in COPD  
Accidental fall rates are high in the COPD population (Beauchamp 2019; Roig et al. 2011) and are 
associated with poor walking stability (Iwakura et al. 2019; Lahousse et al. 2015; Marques et al. 2017; 
Yentes et al. 2015; Zago et al. 2018) and poor balance control (Beauchamp et al. 2009; Porto et al. 
2015).  Unintentional falls are likely to contribute to the large disease burden of COPD and may 
significantly reduce a person’s quality of life (Brooke 2013; Hellstrom et al. 2009).  Not only is the 
probability of falling high in this population, but the likelihood of injury from falls, including bone 
fracture and bleeding, are magnified by common comorbidities such as osteoporosis, heart disease, 
anaemia and polypharmacy (Brooke 2013; Lawlor, Patel & Ebrahim 2003a).  Pharmaceutical 
treatment of COPD is non-curative (Vestbo et al. 2013), and listed possible side effects of 
corticosteroid-type medications (used in the treatment of infective exacerbations of COPD) include 
muscle weakness, tendon rupture, hypertension and osteoporosis (Warren 2012).   
 
Exercise therapy, delivered as part of pulmonary rehabilitation, has become a mainstay in 
maintaining physical condition and quality of life in COPD (McCarthy et al. 2015; Vestbo et al. 2013).  
Exercise tolerance is commonly assessed with exertional walking tasks and best practice 
management of COPD involves activities in pulmonary rehabilitation at various levels of intensity 
(McCarthy et al. 2015; Mukundu 2015).  Utilising established walking assessments may offer a safe 
method for determining the impact that maximal or near maximal effort may have on gait variability 
or balance control.  If increased exertion affects balance control during or immediately after walking, 
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Risk factors for falls in COPD  
Researchers have identified common risk factors for accidental falls in the COPD population (Bhosle, 
Alaparthi & Krishnan 2012; Crisan et al. 2015; Oliveira et al. 2013; Roig et al. 2009).  There is a 
consensus in the literature that people with COPD (compared to age and sex-matched healthy 
adults) have increased risk factors such as poorer balance, reduced lower limb muscle power, and 
reduced postural control (Bhosle, Alaparthi & Krishnan 2012; Crisan et al. 2015; Janssens et al. 2014; 
Oliveira et al. 2013; Roig et al. 2009).  Gait impairments are recent additions to the list of validated 
risk factors specific to fallers with COPD (Lahousse et al. 2015; Yentes et al. 2011).  Levels of exertion 
have not been researched as a risk factor for accidental falls, despite evidence that people with 
COPD fatigue easily (Boccia et al. 2015) and require a high physiological energy to perform walking 
tasks (Marquis et al. 2009).  Further research is required to describe how risk factors for falling, 
including postural control and gait variability, are affected by changing levels of exertion.  
 
Gait abnormality and falls in COPD  
Gait impairment is prevalent in COPD, is linked to increased risk of falling and reflects disturbance 
from regular walking patterns across the domains of walking pattern (Lahousse et al. 2015).  Specific 
gait domains impaired in COPD are discussed at length in chapter 2 in the section ‘Gait impairment 
and falls risk in COPD’.  Currently there is little evidence available investigating the relationship 
between gait regularity and exertion levels.  Two large population studies have provided a high level 
of evidence to demonstrate that gait abnormality is associated with increased rates of accidental falls 
in COPD (Lahousse et al. 2015; Yentes et al. 2011).  Additionally, the relationship between falling and 
gait abnormality becomes stronger as COPD severity increases and gait impairment becomes more 
pronounced (Lahousse et al. 2015).  These findings signpost a relationship between physiological 
changes in COPD and the control of gait regularity, but the exact mechanism behind these 
physiological changes is still unclear. While various patterns of oxygen desaturation during exertion 
Introduction 
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have been reported (Ming-Lung, Lin & Shih-Pin 2014), the impact of oxygen desaturation, or 
increases in carbon-dioxide levels (as markers of exertion) (Chen et al. 2012; Simard, Maltais & 
LeBlanc 1995) on central control of balance and gait is uncertain.  
 
Balance impairment and falls in COPD  
Balance impairment is prevalent in COPD (Beauchamp et al. 2012; De Castro et al. 2016; Jácome et 
al. 2016) and the interplay between balance systems impaired in COPD is complex (Figure 1.1).  
Balance impairment is likely related to increased risk of accidental falls (Oliveira et al. 2017; Ozalevli 
et al. 2011).  People with COPD compared to healthy adults score poorly in many of the commonly 
used measures of balance including the Berg Balance Scale (BBS), Single-Leg Stand time (SLS), and 
Timed Up and Go test (TUG) (Crisan et al. 2015).  The severity of balance impairment correlates with 
risk of falling and is useful as a predictor of falls (Beauchamp et al. 2009).  The exact cause behind 
balance impairment is not verified in the COPD literature (Boccia et al. 2015), but the effect of 
fatigue on balance systems  is one likely mechanism (Marquis et al. 2009).  Balance impairment 
appears to be moderated by participation in pulmonary rehabilitation (Beauchamp et al. 2010; 
Mkacher et al. 2015) but it is unsubstantiated if walking with maximal levels of exertion have a 
negative impact on balance performance.  The relationship between exertion and balance 
impairment is an important area to investigate, as increased exertion levels may place those with 
COPD at increased risk of falls during exercise testing or participating in activities such as pulmonary 
rehabilitation.   
Introduction 
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Figure 1.1 Potential interactions of risk factors for falls in people with COPD 
Adapted from (Roig et al. 2009) 
 
Significance of Study  
Unknown risk of fall with exertion  
There is a lack of clinical guidance on safe exertion thresholds for the COPD population regarding falls 
risk.  This deficit in clinical direction remains, despite pulmonary rehabilitation being established as 
the non-pharmaceutical treatment of choice for managing COPD symptoms.  Several systematic 
reviews of exercise therapy interventions have established pulmonary rehabilitation as beneficial for 
improving functional balance, dyspnoea, exercise capacity, strength, and walking stability in COPD 
populations (Jacome et al. 2014; McCarthy et al. 2015; Mukundu 2015).  Pulmonary rehabilitation is 
Introduction 
Page | 8  
 
widely used in the management of COPD, yet few studies investigating safe levels of exertion for 
participation in exercise therapy have been conducted (Camp et al. 2015).  Further study is justified 
to determine safe levels of exertion to manage a potential increased risk of falling during periods of 
increased exertional effort.   
 
Research Questions  
The primary aim of this study is to determine if people with COPD have increased risk of falling while 
participating in activities that require elevated or near maximum levels of exertional effort.  The 
study seeks to determine if maximum levels of exertion produce a deterioration in gait regularity 
during exertional walking tests, and if dynamic balance control reduces directly after exertional 
testing while measures of exertion remain high.  The study is designed to utilise internally-paced as 
well as externally-paced walking tests to ensure both a self-regulated maximum exertion is achieved 
and exertion at the voluntary limit is reached.   
 
Hypotheses premise  
Because people with COPD have gait impairment and reduced balance control it is possible that 
increased levels of effortful walking could further compromise walking stability and increase their 
risk of accidental falls.  It is hypothesised that the walking pattern becomes less regular with 
increased exertion and balance control is reduced immediately after effortful exertion in COPD.  A 
secondary hypothesis is that there is a positive correlation between increasing exertion levels 
experienced in clinical walking tasks and a decrement in gait regularity and balance control in people 
with COPD.  It is postulated that increased walking exertion will compromise physical systems 
required to maintain an even walking pattern and reduce dynamic balance control, introducing an 
increased susceptibility to accidental falls.   
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CHAPTER 2  
Literature review 
Literature search method 
To inform this literature review a systematic approach and authors topic knowledge was used to 
search the following online databases between 2015 and 2019:  
• Scopus (http://www.scopus.com ,  
• Google Scholar (https://scholar.google.com),  
• web of science (https://mjl.clarivate.com),  
• PubMed (https://www.ncbi.nlm.nih.gov/pubmed), and  
• The Cochrane Database (https://www.cochranelibrary.com ).   
The following keywords and subject headings were used in the search: COPD, Definition, 
Management, Morbidity, Mortality, Chronic Disease, Osteoporosis, Cognition, COPD exacerbation / 
acute exacerbation, Walking-test, Six-minute walk test, Incremental shuttle walk test, Falls, 
Accidental falls, Risk Factors, Gait, Gait impairment / variability, Walking pattern, Balance, Functional 
balance, Balance assessment/tests, Postural control, Functional Reach, Pulmonary rehabilitation, 
Quality of life, Exercise, Exertion, Effort.  Guidance and published studies identified in the search 
were limited to articles written in English, published within the last 5 years (unless to describe history 
or background), and peer reviewed.  Articles not included in the literature review were studies that 
used a qualitative methodology, published in a language other than English, and studies lacking peer 
review.   
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Introduction 
Overview of this research project  
COPD is a chronic lung airflow condition with an undisputed large body of evidence showing it to be 
one of the leading and increasing global causes of death and disease burden (Mirza et al. 2018; 
Vogelmeier et al. 2017).  The considerable economic and social burden of COPD (Soriano et al. 2017) 
has prompted substantial research in the area of disease assessment and treatment.  
Extrapulmonary effects of COPD have been well documented for over two decades now (Agustí et al. 
2003) but areas of research focus are probably diversified and diluted by the fact that COPD affects 
multiple body systems and processes.  Despite this, accidental falls and subsequent injury such as 
fragility fractures are an area of research that overlaps both the older adult population and COPD 
population and there are multiple systematic reviews identifying validated risk factors of falling 
which are applicable to both groups (Gillain et al. 2018; Ryrso et al. 2018; Sousa et al. 2017).   
 
Research in the area of falls in COPD was initiated by randomised controlled trials that were 
commonly limited by small participant numbers, the absence of consensus on outcome measures, 
and no subcategorising of the COPD population (Beauchamp et al. 2009; Roig et al. 2009).  Since then 
stride-to-stride variations in gait patterns have emerging as a predictive tool for distinguishing 
between fallers and non-fallers in COPD (Liu et al. 2017; Nantsupawat et al. 2015; Yentes et al. 2015).  
This research development has probably been enabled by advances in technologies that map 
spatiotemporal gait patterns such as walking mats and accelerometers.  Currently large observational 
studies are available that describe gait characteristics in COPD versus non COPD older adults (De & 
Bhuniya 2015) and systematic reviews have substantiated increased gait variability to be a falls risk in 
the COPD population (Gillain et al. 2018; Marques et al. 2017).   
 
A promising and emergent area of research in the domain of COPD and falls is the challenge to 
establish a consensus on which spatiotemporal gait measures are most reliable in differentiating 
between fallers and non-fallers and how these measures should be conducted in a clinical setting.  
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Increased variability in stance and stride time has been convincingly observed in the COPD 
population (Lahousse et al. 2015) and is probably a good indicator of increased falls risk when 
walking (Heraud et al. 2018; Lahousse et al. 2015; Liu et al. 2017).  Yet, these findings are still to be 
verified at the level of systematic analysis and review and no data on minimal clinically important 
difference is in circulation.  Another shortfall in the available research is the fact that most gait 
analysis is performed at self-selected velocity or at set velocities above and below self-selected pace.  
This observation method does not match real life situations or even common clinical practice.  
Consequently, this is the first study designed to measure gait variations at or near maximum exertion 
in a way that can easily be replicated in a clinic setting. 
 
An imperative clinical question is addressed in this thesis, the question of how gait variance responds 
to raised exertion levels.  This research question is particularly relevant as currently there is a paucity 
of COPD research giving clear direction on which gait parameters might change at different exertion 
intensities.  Exertional walk tests have long been reported in systematic reviews as safe, used 
routinely for exertion testing and are useful for staging and prognostication in COPD (Andrianopoulos 
et al. 2015; Ho & Maa 2016).  Despite this, prior to this current piece of research, it has not been 
established if walking at or near maximum levels of exertion results in altered gait regularity.  The 
benefit of combining the utility of gait assessment technology and exertion monitoring is that it may 
provide guidance on early detection of falls risk, give direction on safer exercise testing and therapy 
methods, and deliver deeper insight into which areas of gait and exertion are most closely related.   
 
Definition and magnitude of COPD 
Chronic Obstructive Pulmonary Disease (COPD) is a “lung disease characterized by chronic 
obstruction of lung airflow that interferes with normal breathing and is not fully reversible” (WHO 
2015a; World-Health-Organisation 2015).  It is a collective term describing chronic inflammation of 
the central airways and may predominantly involve emphysema and chronic bronchitis disease 
processes (WHO 2015a; World-Health-Organisation 2015).  The lung disease is considered:  
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• Preventable:  COPD is believed to be caused by smoking tobacco (estimated cause of 40% to 
70% of COPD cases) and exposure to air pollution (WHO 2015a; World-Health-Organisation 
2015); 
• Treatable:  Pharmaceutical and non-pharmaceutical management aims are to reduce risk 
factors, minimise symptoms and infective exacerbations, and prevent secondary 
complications (Lisy, White & Pearson 2014); or  
• Incurable:  The disease is progressive and a leading cause of death globally (Lozano et al. 
2012; Vogelmeier et al. 2017). 
 
Diagnostic criteria COPD 
Spirometric measurement of airflow limitation has been used as one of the key diagnostic criteria for 
COPD (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive 
Pulmonary Disease 2020 REPORT  ; Halbert et al. 2006; Vollmer et al. 2009).  Because severity of 
airflow limitation has only a weak correlation with disease symptoms and health status (Global 
Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 
2020 REPORT)the Global Initiative for COPD uses four key aspects of the disease to assesses the 
disease impact, these are: 
• The presence and severity of the spirometric abnormality  
• Current nature and magnitude of the patient’s symptoms 
• History of moderate and severe exacerbations and future risk 
• Presence of comorbidities 
(Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary 
Disease 2020 REPORT).  Spirometric values, taken after an adequate dose of an inhaled 
bronchodilator, are used to classify the severity of airflow limitation and a post-bronchodilator fixed 
ratio of Forced Expiratory Volume in 1 second / Forced Vital Capacity (FEV1/FVC) < 70 is the 
recognised benchmark to determine airflow obstruction (Mirza et al. 2018), airflow limitation is then 
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categorised into four levels based on FEV1 impairment (Table 2.1).  Restricted airflow and infective 
exacerbations of COPD are thought to be responsible for the well-noted exercise impairment of the 
cohort (Vogelmeier et al. 2017).  
Table 2.1 Classification of airflow limitation severity in COPD  
Classification of airflow limitation severity in COPD (Based on post-bronchodilator FEV1)  
in patients with FEV1/FVC < 0.70: 
GOLD 1  Mild FEV1 ≥ 80% predicted 
GOLD 2  Moderate 50% ≤ FEV1 <80% predicted 
GOLD 3  Severe 30% ≤ FEV1 <50% predicted 
GOLD 4  Very severe FEV1 < 30% predicted 
(Mirza et al. 2018) 
 
Prevalence, morbidity impact, and mortality of COPD 
COPD is a prevalent and widespread condition affecting populations worldwide, with an estimated 
prevalence of 251 million cases of COPD globally in 2016 (Mathers & Loncar 2006).  Globally, it is 
ranked as the fourth leading cause of death (Mirza et al. 2018), and despite possible under-reporting 
(Halbert et al. 2006), COPD is predicted to become the third largest cause of death by the year 2020 
(Vogelmeier et al. 2017).  COPD is an important global health problem that is a major cause of 
morbidity and mortality.  Many people suffer directly from the disease, from secondary 
comorbidities, and have increased risk of early mortality (Mirza et al. 2018).   
 
The morbidity impact of COPD is substantial both nationally and internationally.  In Australia, COPD 
has been identified as the third leading cause of disease burden (Brooke 2013).  Internationally, in 
the year 2015, COPD accounted for 2·6% of global disability-adjusted life years (Soriano et al. 2017).  
Multimorbidity in COPD is prevalent with most people having at least one other comorbidity and 
many having multiple (Vanfleteren et al. 2013).  COPD has complex interactions with other 
comorbidities and is likely to contribute to falls (Hanlon et al. 2018).  A cross-sectional study in the 
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UK of community-dwelling adults (COPD n= 8317; no COPD n= 494 323) found multimorbidity ( ≥ 4 
conditions) to be present in 17% of those with COPD versus 4% in those without COPD (Hanlon et al. 
2018).  Multimorbidity is likely to contribute to disease severity and mortality, and it increases with 
age (Hanlon et al. 2018). 
 
COPD is a major cause of mortality globally, and deaths from COPD have been increasing over the 
past 30 years (Yohannes et al. 2016).  In Australia, COPD is placed fifth in the leading causes of death 
(Brooke 2013). Internationally, an estimated 3.2 million deaths were caused by the disease in 2015 
(5% of all deaths globally), which is an 11.6% increase from the year 1990 (Soriano et al. 2017).  
Patients with COPD have high mortality rates and falls in COPD are an established predictor of 
mortality risk (Yohannes et al. 2016).  A one-year mortality rate study of 898 patients with severe 
COPD who received inpatient care at a rehabilitation hospital, documented over one year, had an all-
cause mortality rate of 22% (Yohannes et al. 2016).  A regression analysis revealed that having a 
history of falls in the 6 months preceding and dyspnoea during activities were predictors of morbidity 
(OR= 3.05; 95%CI: 1.40 to 6.66; P= ≤ .005) and mortality (OR= 1.05; 95%CI: 1.02 to 1.08; P≤ .002) 
respectively (Yohannes et al. 2016).  
 
Acute Exacerbation Episodes of COPD  
An exacerbation of COPD is an acute worsening of respiratory function that requires more therapy 
(Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary 
Disease 2020 REPORT).  The worsening of respiratory symptoms includes increased dyspnoea, cough, 
sputum production and sputum purulence (Kim & Aaron 2018).  Acute exacerbations of COPD are 
classified: 
• Mild – if treated with short-acting bronchodilators only;  
• Moderate – if treated with short-acting bronchodilators plus antibiotics and/or oral 
corticosteroids; or  
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• Severe – if the patient visits the emergency room or requires hospitalisation because of an 
exacerbation (Vogelmeier et al. 2017). 
 
Most exacerbations are triggered by viral infections, but exacerbations can also be initiated or 
worsened by bacterial infection, air pollution, or climate changes (Global Strategy for the Diagnosis, 
Management, and Prevention of Chronic Obstructive Pulmonary Disease 2020 REPORT).  The causes 
of acute exacerbations of COPD (and estimated prevalence) include: viral infection (30-60%), 
bacterial infection (30-50%), eosinophilic inflammation (20%), congestive heart failure (6-8%), 
pneumonia (6-8%), poor medication adherence (5%), and pulmonary embolism (3%) (Kim & Aaron 
2018).   
 
Acute exacerbations of COPD are associated with lost work productivity, increased utilisation of 
healthcare resources, temporary or permanent reductions in lung function and exercise capacity, 
hospitalisation, and sometimes death (Kim & Aaron 2018).  Exacerbations of COPD are associated 
with increased dyspnoea, reduced muscle strength, balance impairment, and increased risk of falling 
(Oliveira et al. 2017).   
 
The frequency and severity of respiratory exacerbations are positively correlated with exercise 
impairment, reduced balance, and lowered stability performance (Alahmari et al. 2014).  A 
prospective study of 73 people with COPD recorded their daily step count over a 12-month period to 
classify the participants into a frequent exacerbation group ( > 2/year) or infrequent (Alahmari et al. 
2014).  Results demonstrated that mean daily step count fell from a 4154 steps/day baseline to 3673 
steps/day during days of exacerbation and that the stepping pace was faster in untreated compared 
to treated exacerbations (Alahmari et al. 2014).  COPD exacerbations are likely to result in physical 
inactivity, and frequent exacerbations accelerate deconditioning over time (Alahmari et al. 2014).  
Even mild episodes of acute exacerbation that do not require hospitalisation are associated with 
reduced activity levels and reduced leg strength (Alahmari et al. 2016).  Mean Six-Minute Walking 
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Distance (6MWD), when measured in 97 episodes of COPD exacerbation, fell significantly from 422 m 
(when stable) to 373 m (on day 3 post-exacerbation) (Alahmari et al. 2016).  In the same study, 
quadriceps maximum voluntary contraction fell from 32.6 kg to 29.7 kg (Alahmari et al. 2016).   
 
Evidence suggests that balance control is also impaired during episodes of COPD exacerbation.  The 
Berg Balance Scale (BBS), Single Leg Stance (SLS), and Timed Up and Go Test  (TUG) were assessed as 
measures of balance control in 29 people with stable COPD, 17 people with acute exacerbation, and 
17 people with matched demographics as a healthy control group (Crisan et al. 2015).  The stable 
COPD and acute exacerbation group were significantly associated with reduced balance control: BBS 
reduced from 55/56 (control), 53/56 (COPD), and 44/56 (acute exacerbation); TUG increased from 
8.6 sec (control), 12.3 sec (COPD), and 15.9 sec (acute exacerbation); SLS reduced from 31.1 sec 
(control), 17.7 sec (COPD), and 7.2 sec (acute exacerbation) (Crisan et al. 2015).  Results from the 
above studies indicate that people with COPD have reduced exercise capacity, reduced leg strength, 
and impaired balance particularly during periods of acute exacerbation.  It is reasonable to expect 
that during times of COPD exacerbation the risk of falling is higher.    
 
Falls are an extrapulmonary COPD presentation 
Typical pulmonary symptoms of COPD include breathlessness, sputum production and cough (Lisy, 
White & Pearson 2014).  Extrapulmonary effects of COPD influence multiple body systems and have 
a wide-reaching scope.  Extrapulmonary or systemic effects of COPD have been recognised in the 
COPD literature for over a decade (Agustí et al. 2003).  They include exercise limitation, skeletal 
muscle dysfunction, metabolic dysfunction, and weight loss (Agustí et al. 2003).  High accidental falls 
rates (Roig et al. 2011), poor postural control (Porto et al. 2015) and abnormal gait (Lahousse et al. 
2015) are more recent additions to extrapulmonary complications in COPD that have a profound 
effect on quality of life measures (Arne et al. 2009).  The World Health Organisation defines an 
accidental fall as “an event which results in a person coming to rest inadvertently on the ground or 
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floor or other lower-level” (WHO 2019).  The impact of accidental falls in particular, has been 
demonstrated to be a significant contributing factor to disease burden in COPD (Hakamy et al. 2018). 
 
Exertional walk tests are an important element of COPD assessment and commonly used during 
pulmonary rehabilitation to ascertain an individual’s physical function (Ho & Maa 2016).  The Six-
Minute Walk Test (6MWT) and Incremental Shuttle Walk Test (ISWT) are the two most commonly 
used field walking tests and should be used at regular intervals to establish disease severity (Mirza et 
al. 2018).  Clinical walk tests are considered a safe way of evoking exertion, but few studies are 
available to advise on safe exertional parameters during testing or the impact maximum levels of 
exertion has on gait variability or stability.  As discussed further in this chapter under various sections 
this area of investigation has clinical significance as it is unknown if there is a threshold point at 
which increased exertion places people at greater risk of falling.   
 
Falls risk factors in community-dwelling adults  
Risk factors for accidental falls in the general population are diverse and can be defined as an 
“increased susceptibility to falling that may cause physical harm” (Sousa et al. 2017).  A systematic 
literature review on risk factors for falls identified 62 studies describing  50 individual falls risk factors 
(Sousa et al. 2017).  Recognised risk factors for falling in community-dwelling adults cover 
demographic, environmental, medication, cognitive, physiological, psychological, and socio-
economic risks (Table 2.2) (Sousa et al. 2017).  Interestingly, COPD is identified as an individual risk 
factor.   
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Table 2.2 General Risk Factors for Falls Identified in the Literature 
Risk Factors for Falls 
Demographics Physiologic 
Age ≥ 65 years* 
History of falls*  
 Use of assistive device/s 
Female * 
Change of blood sugar  
Vascular disease 














Difficulty in gait* 
Compromised balance 







 Antihypertensive agents  
 Benzodiazepines 
Cognition 
 Change in cognitive function 
Diminished executive functions 
Psychological 
Fear of falling* 
Depression 
Anxiety 
*Risk factors more common in COPD 
Adapted from Sousa et al. (2017) 
 
Gait variability and velocity as fall predictors in community-dwelling adults 
Aberrant spatiotemporal stride-to-stride fluctuations have a positive association with increased risk 
of falling (Hausdorff, Rios & Edelberg 2001) and appear to worsen with age (Callisaya et al. 2010).  A 
systematic review to assess the utility of accelerometric methods to identify older adults at risk of 
falling yielded ten cross-sectional studies and identified people that are at risk of falling as those who 
walk slower, walk with shorter steps, have lower step frequency, have worse stride and step 
regularity in terms of time, position and acceleration profiles (Gillain et al. 2018).  A systematic 
review of the spatiotemporal parameters of gait capable of distinguishing an elderly faller from a 
non-faller has likewise been conducted (Mortaza, Abu Osman & Mehdikhani 2014).  Results from this 
review identified fallers to have slower walking speed and cadence, longer stride time, and double 
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support duration, shorter stride and step length, wider step width, and more variability in 
spatiotemporal parameters in gait (Mortaza, Abu Osman & Mehdikhani 2014).  Gait speed per 0.1 
m/s decrease has an elevated Risk Ratio (RR= 1.07; 95%CI: 1.00 to 1.14) for falling (Verghese et al. 
2009).   
 
Falls in COPD  
Prevalence of falls in COPD 
The COPD population has a much higher falls rate and rate of repeat falls than matched community-
dwelling adults (Ambrose, Paul & Hausdorff 2013; Bozek et al. 2019; Hakamy et al. 2018; Oliveira et 
al. 2015; Sousa et al. 2017).  Community-dwelling adults typically have a falls rate of 29 to 33% 
(Bongue et al. 2011; Tromp et al. 2001), but if grouped by specific disease, classification can increase 
to 54% (Delbaere et al. 2010).  Rates of repeat fallers in community-dwelling adults are estimated at 
10 to 20% (Gregg, Pereira & Caspersen 2000).  A large United Kingdom primary health database 
study found those with COPD to be 55% more likely to have a health record of a fall than non-COPD 
(Hakamy et al. 2018) and to have a larger rate of repeat falls as the falls incidence per 1000 person-
years was 44.9 (95%CI: 44.1 to 45.8) in COPD compared to 24.1 (95%CI: 23.8 to 24.5) in non-COPD 
(Hakamy et al. 2018).  Further evidence of this trend can be found in a twelve-month prospective 
study which found 40% of community-dwelling adults with stable COPD fell and 75% of the COPD 
fallers had frequent falls (Oliveira et al. 2015).  Other studies estimate falls prevalence in community-
dwelling adults with COPD to be between 44 and 51% (Beauchamp et al. 2009; Beauchamp et al. 
2012; Roig et al. 2011).   
 
Injury and bone fracture from falling in COPD 
The rate of severe injuries such as fragility fractures are more prevalent in COPD than community-
dwelling adults (Huang et al. 2016; Jorgensen et al. 2014; Yamauchi et al. 2016) and is a substantial 
contributor to disease burden.  Fractures of the hip are the most common fracture site leading to 
admission to hospital in COPD, and the high rate of hip fracture in COPD is important as it has a 
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stronger association with mortality than other fracture types (Yamauchi et al. 2016).  Jorgensen et al. 
(2014) give an incidence rate ratio for hip fracture and proximal humeral fracture in COPD of 1.43 
(95%CI: 1.39 to 1.46) and 1.24 (95%CI: 1.19 to 1.29) respectively.  Huang et al. (2016) give a 
covariate-adjusted hip fracture hazard ratio of 1.57 (P= ≤.001).  A large retrospective study of 
patients admitted with a primary diagnosis of hip fracture over a 10-year period (2004 to 2013) 
found hip fracture cases per 100,000 increased from 312 to 427 (115 cases) in those with COPD, and 
from 284 to 314 (30 cases) in those without COPD (de Miguel-Diez et al. 2016).  Hip fracture is more 
prevalent in those with COPD than those without and accounted for 6.9% of those admitted with hip 
fracture (de Miguel-Diez et al. 2016).   
 
A high rate of bone fracture from accidental falls in COPD may be due to a high co-presentation of 
osteoporosis (Corsonello et al. 2011; Lu et al. 2017).  A 2002 review gave the prevalence of 
osteopenia in COPD to be 35 to 72% and osteoporosis at 36 to 60% (Biskobing 2002).  A more recent 
systematic review in 2009 gave the prevalence of osteoporosis and osteopenia to be 9–69% and 27–
67% respectively in COPD (Graat-Verboom, Wouters, Smeenk, et al. 2009).  The fracture rate of 
COPD people who fall is 36.3% compared to 7.3% in age- and gender-matched healthy adults 
(Gazzotti et al. 2019).  Authors of the study attribute the high rate of fracture to the high prevalence 
of osteoporosis in the COPD group, as they found 29.7% of those with COPD to have a 
co-presentation with osteoporosis, compared to only 18.3% in the control group (p= .007) (Gazzotti 
et al. 2019).   
 
The high prevalence of osteoporosis in COPD is associated with the prescribed dose of steroid used 
to manage the condition and the duration of exposure to the drug (Lu et al. 2017).  The use of oral 
corticosteroids with a large cumulative defined daily dose has a hazard ratio for developing 
osteoporosis of 1.85 (95%CI: 1.52 to 2.26) (Lu et al. 2017).  Lu et al. (2017) reports an incidence of 
osteoporosis in people with COPD as 1,343 per 100,000 person-years but this rate varies between 
studies.  The dose and duration of steroid medication exposure may explain the discrepancy in the 
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reported incidence of osteoporosis and osteopenia in COPD and why the amount of volumetric bone 
mineral density loss increases as the disease progresses.  Jaramillo et al. (2015) found 58% of people 
with COPD to have low bone mineral density versus 84% in those with very severe COPD.  It is likely 
that as the disease progresses, the exposure and dose of inhaled corticosteroids increases, while at 
the same time weight-bearing activity decreases.  To compound this effect, deconditioning processes 
may increase the risk of falling.   
 
COPD specific risk factors for falling 
Demographic risk factors for falls in COPD  
The COPD demographic is an older-adult population, and disease severity typically worsens with age 
due to the cumulative effect of repeated exposure to air contaminants (Mercado, Ito & Barnes 2015).  
According to a large cross-sectional study ( > 200,000 households over eight countries), the mean age 
of people with COPD is 63.3 years, 55.8% of whom were male and 44.2% female (Rennard et al. 
2002).  A more recent study (surveying > 100,000 households across twelve countries) showed that 
females are now more likely to have COPD than males (52% vs 48% respectively) and that the age of 
onset is dependent on geographic location (Landis et al. 2014).  The combined summary of these 
papers is that average COPD age is decreasing and the proportion of females with COPD is increasing.  
Both these factors are important, as both older age and female sex are risk factors for falling (Sousa 
et al. 2017).   
 
Medication risk factors for falls COPD  
Polypharmacy has been established as an independent falls risk factor (Sousa et al. 2017).  
Prescription of multiple medications is associated with multimorbidity, is more common in older 
adults, and can be listed as appropriate or inappropriate polypharmacy (Masnoon et al. 2017).  There 
is no accepted definition of polypharmacy, but a systematic review of polypharmacy definitions 
indicates the consensus number of prescribed medications is more than or equal to five medications 
(Masnoon et al. 2017).  A prospective study of falls in people with COPD identified those that take 
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multiple medications to have an incidence rate ratio of 1.15 (95%CI: 1.00 to 1.34) falls per person-
years (Oliveira et al. 2015).  This finding is supported by a matched cohort study of a United Kingdom 
primary care database in which COPD was reported to have higher rates of multimorbidity (17% 
compared to 4% in non-COPD) and higher levels of polypharmacy (52% with COPD compared to 18% 
in non-COPD) (Hanlon et al. 2018).  Interestingly, a large study investigating determinants to poor 
adherence to pharmacological treatment discovered that 59.5% (n= 13381) of the COPD participants 
were taking ≥ 5 medications, and polypharmacy was positively associated with poor adherence to 
prescribed medication regimens in the persons ≥ 65 years old (OR= 1.34; 95%CI: 1.13 to 1.59) 
(Vetrano et al. 2017). 
 
The type of medications people take, and the interactions between medications also influence the 
risk of falling (Ambrose, Paul & Hausdorff 2013).  A literature review of risk factors for falling in older 
adults identified psychotropic medications, diabetes medications (for increased risk of traumatic 
fracture), nonsteroidal anti-inflammatory drugs, cardiovascular medications, antiepileptics and 
medications for depression as factors that increase likelihood of accidental falls (Ambrose, Paul & 
Hausdorff 2013).  A more recent literature review on medications associated with risk of falling found 
the following classes of prescription medications to be associated with falls in the general older 
population: sedatives, hypnotics and antidepressants, including tricyclic antidepressants, selective 
serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors (Park et al. 2015).  
Both reviews above site mood-altering medication for the treatment of depression as a medication 
class associated with falls.  This finding is important in the COPD population as depression prevalence 
in COPD can be as high as 80% (Pollok, van Agteren & Carson-Chahhoud 2018) and more than one 
third can experience depression and anxiety (Panagioti et al. 2014). 
 
There is a lack of studies designed specifically to investigate the role of polypharmacy or the use of 
specific types of medications in relation to increasing the risk of falling in COPD, however high rates 
of polypharmacy is identified in the COPD cohort (Hanlon et al. 2018).  A cross-sectional survey study 
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collected baseline assessment data from 502,640 community-dwelling participants aged 37 to 73 to 
evaluate the pattern and extent of multimorbidity and polypharmacy in COPD group (Hanlon et al. 
2018). This study found participants with COPD (n= 8317) were significantly more likely than those 
without (n= 494,323) to be prescribed ≥ 3 medications contributing to a greater risk of reporting 
adverse drug reactions including falls (OR 2.27; 95%CI: 2.13 to 2.42) (Hanlon et al. 2018).  In the same 
study, authors state that those with COPD were more likely to take multiple medications and have 
adverse drug reactions than any other chronic condition category.   
 
Medications required for effective management of COPD appear to contribute toward, but not be 
solely responsible for, all skeletal problems in COPD.  Sex, older age, and use of a high oral 
corticosteroids dose increased the risk of osteoporosis with a hazard ratio of 1.85 (95%CI: 1.52 to 
2.26) (Lu et al. 2017).  Fragility fractures from low bone mass is common in COPD, but medication use 
is not the only risk factor associated is osteoporosis in this cohort (Misof et al. 2016).  Risk factors 
other than medications include systemic inflammation, tobacco smoking, and vitamin D deficiency 
(Misof et al. 2016).  Despite the existence of multiple risk factors, glucocorticoids and other 
corticosteroids are common frontline medications for both maintenance and management of 
exacerbations, and they appear to be a strong contributor to bone changes in COPD (Misof et al. 
2016).   
 
Physiological risk factors for falls in COPD  
Physiological risk factors for falling validated in non-respiratory conditions such as lower limb 
weakness and reduced postural control (Roig et al. 2009) are also prevalent in the COPD population.  
Multiple body systems required for safe and stable locomotion are impaired in COPD.  Factors listed 
to be associated with impaired postural control and falls in COPD include muscle weakness, physical 
inactivity, older age, need for supplemental oxygen, and limited mobility (Porto et al. 2015).  Severity 
of oxygen dependency (Roig et al. 2011), dyspnoea and impaired balance (Beauchamp et al. 2009; 
Ozalevli et al. 2011), activity avoidance and deconditioning (Hellstrom et al. 2009), as well as gait 
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impairment (De & Bhuniya 2015) are all associated with falling in COPD.  Fallers with COPD have 
impaired gait rhythm which is an impairment that is positively correlated with severity of airflow 
limitation and high frequency of infective exacerbations (Lahousse et al. 2015).  Gait impairment has 
emerged as a reliable predictor of falls in COPD (Zago et al. 2018).  Each of the above physical risk 
factors for falls is explored in more depth in the following sections. 
 
Morbidity and disease burden associated with falls  
Many chronic diseases are independently associated with a high incidence of accidental falls and the 
presence of multiple chronic diseases is considered a falls risk factor (Paliwal, Slattum & Ratliff 2017).  
A cross-sectional survey study found chronic disease to be an important predictor of falling and 
ranked COPD second among common chronic diseases associated with falling (Lawlor, Patel & 
Ebrahim 2003b).  Accidental falls contribute significantly to disease burden in COPD.   
 
Multimorbidity as a risk factor for falling in COPD  
Multimorbidity is defined as “the co-occurrence of two or more chronic medical conditions in one 
person” (WHO 2015b) and is a recognised risk factor for injurious falls in older adults (Tchalla et al. 
2014).  COPD is often accompanied by other chronic diseases and perhaps co-present because of 
common risk factors such as tobacco smoking, inactivity and aging, all of which can lead to significant 
morbidity, mortality and economic burden (Lisspers et al. 2018).  Interactions between 
multimorbidity clusters (common morbidity group configurations) have been shown to extend the 
impact of each individual disease process (Tchalla et al. 2014).  Multimorbidity is prevalent in COPD 
(Anecchino et al. 2007; Hanlon et al. 2018) and has been recognised as a risk factor for falls, 
increasing falls, and has been associated with chronic recurring falls (Tchalla et al. 2014).   
 
Historically, the impact of COPD has been measured by the number of visits to a physician, 
emergency department presentations or hospitalisations (Mirza et al. 2018).  These measures are 
inadequate in capturing the effect of multimorbidity clusters such as cardiovascular disease, 
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musculoskeletal impairment and diabetes mellitus (Vanfleteren et al. 2013).  A systematic review of 
the prevalence of osteoporosis and osteopenia in COPD found 35% of people with COPD are likely to 
have osteoporosis (Graat-Verboom, Wouters, Smeen, et al. 2009).  Osteoporosis and sarcopenia are 
important and common comorbidities in COPD (Vespasiani-Gentilucci et al. 2018), and the impact of 
osteoporosis in COPD is reflected in the increased incidence of fractures (Romme et al. 2015).  
People with COPD have higher rates of mortality from hip fracture than other types of bone fracture 
(Yamauchi et al. 2016).   
 
COPD is commonly co-present with osteoarthritis, osteoporosis, or type two diabetes myelitis, and 
produces a disease relationship that is likely to compound falls risk factors, increase the potential for 
accidental falls, and result in injury (Holland, Harrison & Brooks 2016).  COPD and hypertension also 
form a multimorbidity cluster group found to have high falls rates, but further investigation is 
required to study the complex interactions between other chronic health conditions (Paliwal, Slattum 
& Ratliff 2017).  It is likely that impaired postural control and cerebral hypoxemia are factors which 
lead to increased prevalence of falls in people with the co-occurrence of COPD and hypertension 
(Paliwal, Slattum & Ratliff 2017).  As COPD has a high prevalence of multimorbidity, it is associated 
with increased polypharmacy, leading to an increased potential for adverse drug reactions (Hanlon et 
al. 2018).  Polypharmacy alone increases the risk of accidental falls (Sousa et al. 2017), but combined 
with co-occurrence of chronic disease may further compound falls risk.   
 
Gait impairment and falls risk in COPD 
Abnormal gait speed in COPD 
Gait speed and variability is a falls predictor that is prevalent in COPD  
Increased gait variability (Marques et al. 2017) and reduced self-selected walking velocity (Abu 
Samah et al. 2016) are fall predictors identified in older adults and exist more extensively in the 
COPD population than in healthy adults (Lahousse et al. 2015).  Cross-sectional prospective studies 
have described COPD fallers as people who walk slower, more frequently use an assistive device to 
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ambulate, and typically fall while walking outdoors (Roig et al. 2011).  These findings are important 
as reduced gait speed (below 0.6–1.0 m/s) is a standalone gauge for identifying the increased 
probability of falling in older adults (Abu Samah et al. 2016) and associated with survival (Studenski 
et al. 2011).  A large pooled analysis of nine cohort studies using data from community-dwelling 
adults over 65 years old show survival increases with gait speed (Studenski et al. 2011).  In the 
context of this finding it is important to note that walking velocity impairment becomes more 
pronounced as COPD severity progresses (Bousquet et al. 2016; Karpman & Benzo 2014), it is 
therefore reasonable to infer that as COPD severity progresses, gait quality deteriorates and risk of 
falling increases.   
 
Gait speed reduces with COPD severity, indicating a progressive falls risk 
Studies of gait speed in COPD participants indicate that the velocity of walking reduces as COPD 
severity increases (Ilgin et al. 2011; Iwakura et al. 2019; Karpman & Benzo 2014) and that frequency 
of frailty increases (Mittal et al. 2016).  In a large observational study, gait speed using the 6MWT 
was measured and compared with lung function assessment (Ilgin et al. 2011).  Mean gait speed of 
controls and those with mild COPD were significantly slower than in participants in the moderate 
(75.7 m/min), severe (64.3 m/min), and very severe (60.2 m/min) COPD groups (Ilgin et al. 2011).  
Slower gait speed was also significantly correlated with increasing dyspnoea, and poorer scores on a 
questionnaire-based health survey (Ilgin et al. 2011).  The consequence of decreasing gait speed with 
disease progression is increased risk of falling at a stage of the disease where frailty is increasing, 
which further increases the potential for injury, such as a bone fracture.  A study of the correlation 
between gait speed and the presence of frailty in those with COPD revealed that mean gait speed 
was 0.95 m/s in robust participants and 0.68  m/s in frail participants, and that gait speeds slower 
than 1 m/s had a 95% sensitivity to predict frailty (Mittal et al. 2016). 
 
Self-selected walking speed in COPD appears to be limited more by a sensation of dyspnoea and leg 
fatigue than an increase in walking oxygen consumption (Sanseverino et al. 2018).  A study aimed at 
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comparing the economy of walking and gait variability as a function of speed in COPD relative to 
healthy subjects used six treadmill walking speeds and measures of oxygen consumption normalised 
by mass and distance (Sanseverino et al. 2018).  The walking speeds selected were self-selected, two 
speeds above, two below, and a fixed speed of 0.89 m/s.  Walking economy in the control group was 
at its maximum at the self-selected speed, and economy of walking (oxygen consumption over 
speed) worsened at speeds above this speed (Sanseverino et al. 2018).  Conversely, the COPD group 
had increased gait variability and worse economy of walking at slow walking compared to faster 
walking (Sanseverino et al. 2018).  Dyspnoea and leg fatigue in the COPD group increased above the 
self-selected walking speed (Sanseverino et al. 2018).  Supporting these results, a comparison study 
between healthy and COPD participants walking at their preferred speed and ± 20% preferred speed 
demonstrated those with airflow obstruction had reduced energy efficiency with a greater frequency 
ratio of strides to breaths (Yentes et al. 2019). 
 
Spatiotemporal measures of gait are impaired in COPD 
A systematic literature review to evaluate the current understanding of spatiotemporal, kinematic 
and kinetic gait features in patients with COPD identified the predominant gait abnormalities to be 
reduced step length and cadence, increased variability of spatiotemporal parameters, and to a 
smaller degree subtle biomechanical changes at the ankle level leading to reduced foot stability after 
the foot first lands (Zago et al. 2018).  Despite these gait features being identified in COPD, authors of 
the review identified a lack of research describing a persuasive mechanistic link between the listed 
gait impairments and a high incidence of falls in COPD (Zago et al. 2018).  Since 2009, it has been 
identified that further research is required to identify mechanistic links between gait disturbance, 
balance impairment, and falls in COPD (Roig et al. 2009).  However, since this early research occurred 
only a limited number of studies have been conducted in this area and further research is required to 
substantiate and describe gait impairment in COPD as it relates to falls (Zago et al. 2018).  A 
systematic review aimed at understanding the spatiotemporal characteristics of gait in COPD found a 
scarcity of studies, small sample sizes, and pooling of gender and disease status as the main 
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limitations to identifying a causal link between gait impairment and falls in COPD (Zago et al. 2018).  
Despite these limitations, the evidence available indicates that people with COPD have impairment in 
most spatiotemporal measures of gait (Liu et al. 2017), and that the level of gait impairment 
increases with disease severity (Lahousse et al. 2015).   
 
Step time, step width, and step length variability are impaired in COPD 
The increased variability or reduced regularity of step time, width and length may indicate an 
increased risk of falling in COPD (Morlino et al. 2017; Rutkowski et al. 2014; Yentes et al. 2017; 
Yentes et al. 2015).  Step time is measured as the duration that passes while one extremity is on the 
supporting surface in a gait cycle; step width is measured as the distance between two supporting 
steps; and step length is the distance from the point of contact of the heel print of one foot to the 
point of contact of the heel print of the opposite foot (Yentes et al. 2015).  Gait evaluation during a 
6MWT in those with COPD and matched healthy controls identified those with COPD to have 
impaired stance time (left MD= 0.58%, p= .002; right MD=  0.57%, p= .003) and step length (left MD= 
1.77%, p= ≤.001; right MD= 1.74%, p= ≤.001) independent of self-selected walking speed (Liu et al. 
2017).  A similar study corroborating this result found COPD participants over a 6MWT had shorter 
step length and longer step time than controls (Rutkowski et al. 2014).  Both studies had a small 
participant number and did not stratify by disease severity.  An observational study identified 
increased step length variability during a 6MWT to be associated with impaired balance but not FEV1 
or hypoxemia (Morlino et al. 2017).  This result may indicate that increased gait variability may result 
from more chronic changes than transient respiratory changes resulting from walking with exertion.   
 
Stride time and length variability is impaired in COPD 
Stride time and stride length variability may be increased in COPD and be an indicator of increased 
fall risk when walking (Heraud et al. 2018; Lahousse et al. 2015; Liu et al. 2017).  Stride time 
measures the duration between the first foot contact with the ground in two consecutive footsteps 
of the same foot whereas stride length is the distance between successive ground contacts of the 
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same foot.  A small comparison study found stride time variability to be more irregular in COPD 
group than in control group, and a gait distinction that remained after participation in pulmonary 
rehabilitation (Heraud et al. 2018).  Another small comparison study found those with COPD to have 
more stride length variability than controls, irrespective of self-selected walking velocity or 
quadriceps strength (Liu et al. 2017).  Both step time (Lahousse et al. 2015) and step length (Liu et al. 
2017) variability appear to increase in a corresponding pattern with disease severity.   
 
Gait rhythm (stride time variation) in COPD is impaired compared to healthy populations (Annegarn 
et al. 2012; Lahousse et al. 2015); it is also a predictor of falls and positively correlated with airflow 
limitation (Annegarn et al. 2012; Lahousse et al. 2015).  In a 6MWT gait analysis, those with COPD 
have reduced walking-intensity, slower cadence and greater gait variability than healthy participants 
(Annegarn et al. 2012).  This finding is supported by a large cohort study (the Rotterdam study) in 
which gait rhythm variability, phases, pace, tandem, turning and base of support were measured on 
an electronic walkway (Lahousse et al. 2015).  Presence of COPD was found to be associated with 
lower rhythm (independent of age, sex and height), and lower FEV1 was significantly associated with 
variable rhythm, cadence and gait velocity (association remained after adjustment for cognitive 
impairment) (Lahousse et al. 2015).  Another important finding of the Rotterdam study is that people 
with COPD and a history of falling had significantly worse rhythm than non-fallers with COPD 
(Lahousse et al. 2015).   
 
Double support time is impaired in COPD 
It is likely that people with COPD have increased time spent in double support phase of their gait 
(Nantsupawat et al. 2015) and have increased spatiotemporal variability in their overground gait 
patterns than matched healthy adults (Liu et al. 2017).  Double support time is the duration spent 
with both feet contacting the ground during one gait cycle, and the percentage of time spent in 
double support time reduces as gait velocity increases.  A Gait Real-time Analysis Interactive Lab 
based 6MWT was conducted on 80 COPD participants and 38 healthy controls to compare 
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differences in gait patterns between the groups (Liu et al. 2017).  COPD participants had significantly 
increased variability in double support time (MD= 1.18%, p= .001) (Liu et al. 2017).  
 
Mechanisms of gait impairment in COPD  
Some of the suggested mechanisms for gait impairment found in recent studies include fatigue from 
deconditioning, changes in the central processing of balance and coordination (Morlino et al. 2017), 
and reduced ability to deliver oxygen to peripheral muscle tissue (Medeiros et al. 2014).  There is no 
conclusive evidence giving the exact mechanism which leads to gait impairment in COPD, and there 
is only a small number of studies available that investigate the mechanisms of gait impairment.   
 
Fatigue and gait in COPD as a mechanism for gait impairment  
There is some evidence that fatigue in people with COPD may produce increased gait variability 
(Yentes et al. 2015).  A small study aimed at determining the presence of biomechanical gait 
abnormalities in COPD patients (compared to healthy controls) in the condition of rested versus 
fatigued found that the COPD group increased their gait speed and stride length when transitioning 
from rest conditions to fatigue conditions (Yentes et al. 2015).  Also, the control group had an 
associated peak ankle dorsiflexion moment in the transition, whereas the COPD group remained 
constant (p= ≤ 0.01) (Yentes et al. 2015).  This finding is important, as step width variation is 
associated with increased risk of falling (Brach et al. 2005).  Those with COPD compared to matched 
controls have lower leg muscle mass (mean= 8.0 vs. 8.9 kg, respectively) and produced relatively 
lower absolute and leg muscle mass normalised torque (p= ≤.05) (Medeiros et al. 2014).  
Consequently, COPD participants needed greater fractional O2 extraction to produce torque 
compared to controls, indicating that O2 delivery to peripheral skeletal muscle is impaired in COPD 
(Medeiros et al. 2014) and is a possible mechanism of reduced muscle performance.   
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Cognitive impairment in COPD as a mechanism for gait impairment 
Cognitive impairment and executive function loss are independently associated with increased falls 
risk, fall-related injuries, and decreased physical function in community-dwelling older adults (Muir 
et al. 2013).  To establish the epidemiological link between cognitive impairment and fall risk, a 
systematic review and meta-analysis of twenty-seven studies identified impairment of global 
measures of cognition to increase risk of fall and injury with an OR= 2.13 (95%CI: 1.56 to 2.90) (Muir, 
Gopaul & Montero Odasso 2012).  Community-dwelling older adults with even subtle executive 
function impairment have an increased risk of fall (OR= 1.44; 95%CI: 1.20 to 1.73).  There is ongoing 
investigation into which cognitive functions have the most significant impact on the risk of accidental 
fall (Muir, Gopaul & Montero Odasso 2012).   
 
There is a sparsity of studies that directly correlate measures of cognition with falls incidence in the 
COPD population, however cognitive impairment and degradation of executive function have been 
demonstrated to be prevalent in the COPD cohort (Charbek et al. 2019).  A cross-sectional study of 
people with COPD attending a pulmonary ambulatory clinic (n= 106) underwent cognitive 
assessment and cognitive classification (Charbek et al. 2019).  Results showed that 36 (33.9%) 
participants were classified with dementia, 33 (31.1%) had mild cognitive impairment, and 37 
(34.9%) had normal age-appropriate scores.  A reasonable inference is that cognitive impairment (an 
established risk factor for falls) is a contributing factor to the high prevalence in falls because of its 
pervasiveness in this population, yet further investigation is required to establish and clarify this link.   
 
The occurrence of cognitive impairment in COPD is more prevalent than in age-matched healthy 
adults (Lawi et al. 2018) and is one possible mechanism for reduced exercise capacity and increased 
gait variability (Morlino et al. 2017; van Beers et al. 2018).  Hypoxemia, chronic inflammation, dietary 
insufficiencies, reduced physical activity, comorbidity, obstructive sleep apnoea and depression are 
risk factors for cognitive impairment that are often present in COPD (van Beers et al. 2018).  
Cognitive impairment, and in particular executive functioning, is positively associated with reduced 
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exercise capacity and COPD disease severity (Randeep et al. 2019).  A small study of 40 COPD 
participants and 28 control participants correlated measures of lung function, Mini-Mental State 
Examination (MMSE) and dynamic balance to assess the influence of respiratory versus cognitive 
processes on dynamic balance performance (Morlino et al. 2017).  Although proximal muscle 
strength was reduced in COPD, there was no significant correlation with lung function, mental state, 
or balance (Morlino et al. 2017).  Gait speed in the 6MWT was significantly correlated with poor 
balance and poor lung function; the COPD group also had significantly lower MMSE scores than 
controls (p= ≤ .025) (Morlino et al. 2017).  Authors of this study suggested that balance impairment is 
more directly related to central mechanisms such as central nervous lesions.   
 
Balance control impairment and falls risk in COPD 
Many common measures of balance are impaired in COPD (Beauchamp et al. 2012; De Castro et al. 
2016; Jácome et al. 2016).  The impairment appears to worsen at times of acute infective 
exacerbation (Crisan et al. 2015; Oliveira et al. 2017) and may be related to increased frequency of 
accidental falls (Oliveira et al. 2017; Ozalevli et al. 2011).  Both static and dynamic balance are 
impaired in COPD cohorts across the spectrum of disease severity (De Castro et al. 2016).  People 
with COPD have worse BBS scores, reduced SLS time, and slower TUG tests than healthy adults 
(Crisan et al. 2015).  The severity of balance impairment positively correlates with increased risk of 
falling and is useful as a predictor of falls (Beauchamp et al. 2009).  Balance impairment appears to 
be moderated by participation in pulmonary rehabilitation (Beauchamp et al. 2010; Mkacher et al. 
2015), but it is unproven if increased levels of exertion increase balance impairment, making those 
with COPD more at risk during exercise testing.   
 
Balance impairment is common in COPD  
Balance impairment is common in COPD (Porto et al. 2015); it increases with COPD severity (Crisan et 
al. 2015) and may be more pronounced in the bronchitic dominant phenotype (Voica et al. 2016) but 
there is no consensus agreement on the exact mechanism leading to balance impairment.  
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Mechanisms leading to balance impairment are under researched and are probably multifactorial.  A 
systematic review of studies evaluating postural control as a primary outcome in COPD identified 
significant postural control impairment compared to age-matched healthy controls (Porto et al. 
2015).  There is some evidence to suggest that the COPD phenotype may also impact on balance 
performance, because the different phenotypes characteristically have different body composition 
and muscle mass (Voica et al. 2016).  A small-sized study showed people with the bronchitic type 
COPD to have worse scores in Activities-specific Balance Confidence Scale (ABC), BBS, TUG test, SLS 
time, and 6MWT distance compared to people with emphysematous type COPD (Voica et al. 2016).   
 
The exact pathophysiology of the balance impairment in the bronchitic subgroup is unknown, it is 
postulated that body weight distribution, poor exercise capacity, hypoxemia, skeletal muscle atrophy 
and high BMI are contributing factors to worse balance performance (Voica et al. 2016).  An 
alternative mechanism thought to contribute to impaired balance control is the effect chronic cough 
has on pelvic floor muscles, core stability and the ability to regulate intrathoracic and intra-
abdominal pressures (Massery 2009).  Unfortunately, there are few studies available to establish this 
as a contributing factor in reduced balance performance.  A search of the Scopus database using the 
key words ‘chronic cough’, ‘postural control’, ‘falls’, ‘balance’, ‘pelvic floor’ yielded no randomised 
control trials relevant to this area.  One exception is a small study that identified Otago exercise 
program intervention combined with pelvic floor muscle training was more effective than pelvic floor 
muscle training delivered as a control (Yuvarani et al. 2019).  Limitations of this study include small 
size and the use of falls predictive measures rather than fall risk ratio data.   
 
Balance assessment is a predictor of falls in COPD  
Body balance control requires the ability to maintain the bodies centre of mass within perimeter of 
support (Shumway-Cook & Woollacott 2007), it can be measured using various clinical tools and can 
be used to discriminate between COPD fallers and non-fallers (Beauchamp et al. 2009; Ozalevli et al. 
2011).  A cross-sectional study of adults over 60 years old with COPD used baseline measurements of 
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balance and a one year falls diary to conclude that standard clinical measures of balance could 
discriminate between fallers and non-fallers in COPD (Beauchamp et al. 2009).  In this study, 46% of 
the COPD participants sustained a fall; fallers had worse mean BBS than non-fallers of 45.2 (out of 
56) versus 48.8 (p= .042), and poorer TUG mean time of 17 sec versus 14 sec (p= .024) (Beauchamp 
et al. 2009).  In a similar study, Jácome et al. (2016) used the BBS, Balance Evaluation Systems Test 
(BESTest), Mini-BESTest, and Brief-BESTest assessments to discriminate between COPD fallers and 
non-fallers.  Interestingly, each of the balance tests statistically correlated with each other 
(Spearman's rank correlation coefficient: 0.73 to 0.90) but the BBS and the Brief-BESTest had the 
strongest sensitivity and specificity (sensitivity= 73% and 81% and specificity= 77% and 73%, 
respectively) (Jácome et al. 2016). 
 
Relationship between hypoxemia, hypercapnia, and impaired balance control in COPD  
One possible mechanism of loss of stability in the COPD population may be related to central 
hypoxemia and hypercapnia.  COPD falls are more likely to occur in people that are oxygen-
dependent (Roig et al. 2011), and balance impairment is more significant during times of infective 
exacerbation (Crisan et al. 2015; Oliveira et al. 2017).  During periods of infective exacerbation, 
hypoxemia and hypercapnia are more pronounced (Oliveira et al. 2017), and there is a clear positive 
correlation between dyspnoea, arterial oxygen saturation values, and poor BBS scores along with 
increased falls frequency (p≤.05) (Ozalevli et al. 2011).  A higher falls incidence and larger balance 
impairment are present in hospitalised patients with an acute infective exacerbation of COPD 
compared to people with stable COPD (1.76 falls/person/year versus 0.53 falls/person/year, 
respectively) (Oliveira et al. 2017).  The study supports the idea that increased dyspnoea and 
hypoxemia results in reduced physical activity, strength, stability, and increases the risk of falling 
(Oliveira et al. 2017).   
 
Despite chronic hypoxemia being associated with reduced balance control and falls, short bouts of 
exercise-induced hypoxia do not appear to result in accidental fall events during exercise testing.  
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The 6MWT has been used as the mainstay in function assessment in COPD for decades (Guyatt et al. 
1985) and has been proven to be a safe test to administer.  Adverse events occur in 6 to 11% of 
participants, and oxygen desaturation during exercise testing is documented as the most common 
adverse event in the 6MWT (for people with chronic lung disease), however accidental falls are not 
reported amongst adverse events (Afzal et al. 2018; Jenkins & Čečins 2011).  Jenkins and Čečins 
(2011) found that 47% of patients with chronic lung disease had a desaturation of more than 4% in 
SpO2 to lower than 90% during the 6MWT. 
 
Pulmonary rehabilitation for COPD   
Pulmonary rehabilitation is the non-pharmaceutical treatment of choice for COPD (Mirza et al. 2018).  
A Cochrane review of 65 randomised control trials found participation in pulmonary rehabilitation to 
be effective in reducing dyspnoea and fatigue (McCarthy et al. 2015) and that pulmonary 
rehabilitation with a balance component may be effective in mitigation of falls risk factors, as it has a 
demonstrated ability to reduce incidence and frequency of falls (Cruz et al. 2015; Hakamy et al. 2018; 
Hill 2014; Mkacher et al. 2015).  Pulmonary rehabilitation is known as a safe and effective treatment 
modality (McCarthy et al. 2015; Puhan et al. 2016) and can be administered even at times of acute 
exacerbation (McCarthy et al. 2015; Puhan et al. 2016).   
 
Future studies are required to determine which components of pulmonary rehabilitation are 
indispensable, how much oversight participants should have, and the intensity at which participants 
should participate (McCarthy et al. 2015).  Despite the increasing prevalence of pulmonary 
rehabilitation treatment, there are few studies designed to directly examine the direct result of 
raised levels of physical exertion (experienced during pulmonary rehabilitation) on balance control or 
gait regularity.  It is unknown if gait variability or balance control deteriorates at times of increased 
exertion such as during baseline fitness testing or while participating in pulmonary rehabilitation.  If 
pulmonary rehabilitation programs are to become more selective in screening for physical 
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impairment and tailored to individual needs, there is a lack of existing evidence to guide clinicians on 
safe and acceptable levels of exertion for participants.   
 
Definition and function of pulmonary rehabilitation for COPD  
Pulmonary rehabilitation (otherwise known as respiratory rehabilitation) is typically a six to 
eight-week program delivered by a range of health professionals and involves comprehensive 
patient-tailored therapies (Mirza et al. 2018; Puhan et al. 2016).  Pulmonary rehabilitation is defined 
as a “comprehensive intervention based on a thorough patient assessment followed by patient-
tailored therapies that include, but are not limited to, exercise training, education, and behaviour 
change, designed to improve the physical and psychological condition of people with chronic 
respiratory disease and to promote the long-term adherence to health-enhancing behaviours.” 
(Spruit et al. 2013).  Components of pulmonary rehabilitation include exercise, education, self-
management behaviour change, and adherence to health-enhancing behaviours (Mirza et al. 2018).   
 
Pulmonary rehabilitation is considered gold standard care in COPD treatment and is validated by 
systematic reviews as the most effective non-pharmaceutical treatment to improve dyspnoea, 
fatigue, health status, and exercise tolerance (McCarthy et al. 2015).  Therapeutic benefits of 
pulmonary rehabilitation intervention are moderately large, clinically significant (McCarthy et al. 
2015; Puhan et al. 2016) and can last up to 12 months post-intervention (Ryrso et al. 2018).  The 
current best care model for COPD is shifting away from a disease-centric approach and is moving 
towards a patient-centred care paradigm in which interventions such as pulmonary rehabilitation 
provide treatment for complex presentations with multimorbidity (Holland, Harrison & Brooks 2016).  
Aims of pulmonary rehabilitation are to optimise function, augment integration across care settings, 
value-add from multidisciplinary team input, and monitor patient-important outcomes (Holland, 
Harrison & Brooks 2016).  Measures of disease impact in COPD, such as mobility, strength, balance, 
cognition, nutrition, endurance and physical activity also appear to be improved by participation in 
pulmonary rehabilitation (Holland, Harrison & Brooks 2016). 
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Effect of pulmonary rehabilitation on respiratory symptoms in COPD  
People with COPD have increased dyspnoea (Ramon et al. 2018), reduced activity levels compared to 
healthy adults (Albergoni et al. 2019; Saunders et al. 2016), and lower exercise capacity (Blondeel et 
al. 2018).  To investigate the link between dyspnoea and physical inactivity results from a literature 
search were taken to construct and validate the statistical model.  The model commenced with 
airflow limitation, which lead to hyperinflation and dyspnoea, punctuated by COPD exacerbations, 
which leads to physical inactivity, and reduced exercise capacity (Ramon et al. 2018).  Pulmonary 
rehabilitation interventions have a treatment effect on reversing reduced exercise capacity and can 
be implemented close to exacerbations (Puhan et al. 2016; Ryrso et al. 2018).  High-quality evidence 
from a Cochrane review found 6MWT distances to have an average increase of 62 meters (95%CI: 38 
to 86) (Puhan et al. 2016).  Outcomes from a more recent review and meta-analysis also 
demonstrated significant improvement in 6MWT and ISWT distances between early pulmonary 
rehabilitation participation versus usual care (p= ≤ .001 and p= ≤.002, respectively), indicating that 
early commencement of pulmonary rehabilitation was able to improve exercise tolerance (Ryrso et 
al. 2018).   
 
Participation in exercise therapy for eight to twelve-weeks (at an unspecified intensity) has been 
demonstrated to be effective in modifying levels of dyspnoea, reducing fatigue, and improving 
functional exercise capacity (McCarthy et al. 2015).  A 2015 systematic review of randomised control 
trials (RCTs) on pulmonary rehabilitation and measures of physical functional identified 65 RCTs 
containing 3822 participants (McCarthy et al. 2015).  A meta-analysis of the studies revealed 
moderate-quality evidence that participation in pulmonary rehabilitation relieves dyspnoea scores by 
a mean difference of 0.79 units (95%CI: 0.56 to 1.03) and 0.5 units is the recognised minimum 
clinically important difference (McCarthy et al. 2015).  Mean difference in fatigue and maximal 
exercise capacity were also positively affected by participation in pulmonary rehabilitation – 0.68 
units (95%CI: 0.45 to 0.92) and 6.77 units (95%CI: 1.89 to 11.65) respectively (McCarthy et al. 2015).  
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Exercise components include endurance and strength training of varying intensities and durations, 
making it unclear which components of pulmonary rehabilitation have the greatest effect in 
improving shortness of breath, reducing fatigue, and improving exercise capacity (Puhan et al. 2016). 
 
Balance impairment in COPD is mediated by pulmonary rehabilitation  
Pulmonary rehabilitation has been demonstrated to be an effective therapeutic intervention to 
improve strength, exercise tolerance and balance control (McCarthy et al. 2015; Mkacher et al. 2015) 
and is the intervention of choice to reduce falls risk.  Pulmonary rehabilitation with a balance training 
component is more effective at improving balance control and muscle strength than pulmonary 
rehabilitation alone (Beauchamp et al. 2013).  After just six weeks of combined balance exercises and 
standard pulmonary rehabilitation, participants receiving combined intervention achieved 
significantly better results in the BBS (p= ≤.01) and BESTest (p= ≤.01) than the control group receiving 
only standard pulmonary rehabilitation (Beauchamp et al. 2013).  This study indicates that balance 
and muscle strength training in COPD can improve balance measures and subsequently reduce falls 
risk.  A limitation of the study is the concept that a statistically significant difference in balance 
measures does not necessarily equate to a clinically meaningful change in balance. 
 
There is a lack of studies that directly evaluate the effect of pulmonary rehabilitation participation on 
balance control, but the evidence available is favourable toward positive benefits of pulmonary 
rehabilitation (Hakamy, Bolton & McKeever 2017).  A 2017 systematic review of studies evaluating 
the impact of pulmonary rehabilitation on balance and falls only identified two cohort studies on 
balance and no studies that focused solely on falls as an outcome (Hakamy, Bolton & McKeever 
2017).  The studies identified in the review gave some positive benefits of pulmonary rehabilitation 
on balance but found the area to be under-investigated (Hakamy, Bolton & McKeever 2017).  
Balance improvements gained in pulmonary rehabilitation appear to be maintained at least over a 
twelve-month period unless an acute infective exacerbation of COPD occurs (Harrison et al. 2019). 
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Effect of specific balance training versus generalised pulmonary rehabilitation on balance in COPD  
Balance impairment is prevalent in the COPD population and is an important risk factor for accidental 
falls (Neumannová et al. 2017), and may have been omitted in traditional pulmonary rehabilitation 
despite it potentially being a modifiable impairment (Beauchamp et al. 2010; Mkacher et al. 2015).  
Systematic reviews have failed to identify sufficient high-quality evidence supporting pulmonary 
rehabilitation as a treatment that has a large effect on balance measures in COPD (Hakamy, Bolton & 
McKeever 2017; Puhan et al. 2016).  However, randomised control trials have indicated that specific 
balance components integrated into pulmonary rehabilitation are able to improve measures of 
balance in COPD (Beauchamp et al. 2013; Hill 2014; Marques et al. 2015; Mkacher et al. 2015).   
 
Participation in generalised pulmonary rehabilitation may have a small impact on balance control 
(Beauchamp et al. 2010; Pichon et al. 2012), whereas specific balance training as a treatment arm of 
conventional pulmonary rehabilitation may have a more substantial impact on improving balance in 
COPD (Mkacher et al. 2015).  A randomised control trial of COPD participants in either standard 
pulmonary rehabilitation or standard pulmonary rehabilitation with an additional three times a week 
balance training intervention found the control group to improve in TUG tests and ABC scale, and 
Unipodal Stance Test (UST) scores improved (p= ≤ .05) (Mkacher et al. 2015).  Interestingly, a larger 
treatment effect was evident in the intervention group than the control group in the TUG, ABC, UST, 
Tinetti, and BBS scores (p= ≤ .05) (Mkacher et al. 2015).  A similar study of balance adaptations after 
6 weeks of balance training concurrent to standard pulmonary rehabilitation found high compliance 
with the additional training (82.5%) with no adverse effects and a statistically significant 
improvement in BBS (p= .01), BESTest (p= .01), and the 30-second chair-stand test scores (p= .02) 
(Beauchamp et al. 2013).   
 
Pulmonary rehabilitation programs often have a broad-brush approach to inclusion criteria and 
treatment aims, meaning people with COPD are not typically screened for balance impairment.  
Individually tailored therapy programs could result in more effective treatment.  A study of 36 adults 
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with stable COPD and inclusion criteria of decline in balance, fall or near-fall were randomised to 
either standard pulmonary rehabilitation or standard treatment combined with balance-specific 
training (intervention group) (Hill 2014).  The intervention group received additional stance exercises, 
transition exercises, gait exercises and functional strengthening with increasing difficulty, and they 
produced statistically significant improvements in BBS (5.4 units; 95%CI: 2.1 to 8.6) and BESTest 
scores (9.6 units; 95%CI: 3.9 to 15.3) compared to controls (Hill 2014).  There are few other studies 
available to corroborate and expand understanding of these results.   
 
Exertional walking tests for pulmonary rehabilitation in COPD  
Exercise testing is a fundamental component of COPD assessment to determine individual treatment 
needs, stratify disease severity, ascertain baseline level of physical function (Ho & Maa 2016), and 
establish the effect of participation in exercise interventions (Jenkins 2007).  The 6MWT and ISWT 
are two field tests commonly utilised to determine appropriate levels of training intensity and for 
prognostication in COPD (Ho & Maa 2016).  The Global Strategy for the Diagnosis, Management, and 
Prevention of COPD recommend that field walking tests such as the 6MWT and the ISWT be assessed 
regularly to establish disease severity, measure the effect of participation in pulmonary 
rehabilitation, and monitor for a reduction in exercise capacity (Mirza et al. 2018).   
 
The physiological response to the 6MWT and ISWT is similar when comparing end-test changes in 
cardiorespiratory measures but have different intra-tests profiles because of the different 
implementation methods (Holland et al. 2014).  The 6MWT is self-paced and has steady-state oxygen 
uptake after the third minute, whereas the ISWT is externally-paced, and due to the incremental 
nature, has a more rapid rise in oxygen uptake (Holland et al. 2014).  A technical standards document 
adapted from Holland et al. (2014) on standards for field tests for chronic obstructive respiratory 
disease state the 6MWT and the ISWT: 
• have good test-retest reliability (Singh et al. 2014); 
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• are responsive to treatment effects (McCarthy et al. 2015); 
• can elicit similar peak oxygen uptake to values experienced during a cardiopulmonary 
exercise test (Hill et al. 2012); 
• are sensitive to variations in test conditions such as encouragement (Guyatt et al. 1984), and 
other test variations;  and 
• have an identifiable minimal important difference value (30 m for 6MWT distance and 10 m 
for the ISWT) (Holland et al. 2014). 
 
Unknown impact of exertion on walking stability  
Exertional walking tests have been used in clinical practice in the COPD population for decades and 
appear to be safe clinical tests that safely and effectively evoke exertion without placing people at 
undue risk of falling.  Despite prevalent use of the 6MWT and ISWT there are few studies available 
that advise on safe exertional parameters during testing or even identify frequency of observed 
adverse events during testing.  An exception to this trend is a study designed to identify the type and 
frequency of adverse events recorded during the 6MWT, a study of 741 people attending pulmonary 
rehabilitation were recruited (Jenkins & Čečins 2011).  The study identified one event of chest pain, 
one event of tachycardia, and 35 events of oxygen desaturation below 80%, but no fall events or 
near-miss falls were recorded (Jenkins & Čečins 2011).  Another example is a retrospective audit 
conducted to determine if adverse events are associated with desaturation below 80% (during the 
6MWT) which found 11% desaturated below SpO2 80% intra-walk test but not one of the participants 
recorded an adverse event associated with loss of postural control or falling (Afzal et al. 2018).  
Although loss of postural control, poor walking stability, or accidental falls are not reported as 
adverse events that occur commonly during exertional walk tests (Afzal et al. 2018; Jenkins & Čečins 
2011) the ability to identify subtle changes in gait and balance in response to increased exertion is of 
clinical significance as it is unknown if there is a threshold point at which increased exertion places 
people at greater risk of falling.   
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Exertional walking tests are reported to be safe when monitored, however there is a sparsity of 
studies that directly investigate the impact that increased exertion has on gait stability or postural 
control.  Consequently, it is unsubstantiated if effortful walking tests increase the risk of falling 
during or immediately post-test.  Gait variability measures are commonly taken at comfortable 
walking speeds or use normalised velocity.  This practice of gait assessment may not be sensitive to 
changes in gait variation (or postural control) resulting from increasing walking speeds and 
subsequent increased exertion or fatigue.   
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CHAPTER 3  
Methods  
Trial registration 
Australia New Zealand Clinical Trials Registry Number: 12616000030471,  
submitted 14/1/2016; Approved 18/1/2016. 
Tasmanian Health and Medical Human Research Ethics Committee Approval Number: H0015372, 
submitted: 06/11/2015; Approved: 17/12/2015 
 
Aims 
To determine the effect of exertional walking on gait regularity and dynamic balance in adults with 




In people with COPD, increased exertion during walking tasks decreases gait regularity and 
immediately after exertional walking dynamic balance is reduced. 
 
Hypothesis 2 
There is an identifiable relationship between the level of exertion during walking and changes in gait 
regularity in people with COPD. 
 
Study Design 
The study design is a randomised crossover trial conducted with 20 individuals who have COPD and 
attend pulmonary rehabilitation.  Two exertional walking tasks are required to enable a comparison 
between a submaximal (internally paced) walking task and a maximal (externally-paced) walking 
task.   
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The Six-Minute Walk Test (6MWT) is commonly used in clinical assessment because it is time-limited, 
self-paced, and submaximal.  A submaximal walking task will help determine if people can internally 
govern their own level of exertion effectively to maintain a consistent walking pattern.  The 
Incremental Shuttle Walk Test (ISWT) is externally-paced, has set incremental velocities, and is 
conducted to volitional fatigue.  Utilising this test may identify a threshold at which increased 
exertion produces a change in gait regularity.  Walking speeds set to externally-paced velocities are 
likely to minimise the impact of motivational variation and fluctuations in exertion.  Including both 
tests in a crossover design enables comparison between self-paced and externally-paced walking 
patterns while simultaneously comparing the level of exertion to walking pattern consistency.   
 
Data collection occurred over three visits (Table 3.1).  Participants attended on visit number one to 
provide participant descriptive measurements (as described under ‘measures’), have their height and 
weight recorded, and undergo lung function testing.  During visit number two and three, the 
allocated walking task was completed initially, and then again after a thirty-minute rest.  Gait 
variability, exertion, and perceived level of exertion were measured concurrently during each 
walking task.  Dynamic balance was tested before and after each exertional walking task.   
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Participant initiated physical activity monitoring, 
eating, and clothing standardisation prior to 
participation 
Table 3.1 Data collection overview timeline 
 
Randomisation was conducted by a third researcher (not involved in data collection) and undertaken 
using computer software (Motulsky).  Prior to attending visit number two, participants were 
randomly allocated to walking Task A (6MWT) or Task B (ISWT).  At visit two, participants completed 
one of two walk tasks (either Task A or Task B) and then completed the alternative walking task one 
week later, during the third and final visit (Table 3.2).   
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Concurrent to the walking 
task: 
1. Gait variability is recorded 
using a gate sensor mat 
2. Exertion is recorded using 
pulse oximetry and a 
capnograph 
Concurrent to the walking task: 
1. Gait variability is recorded 
using a gate sensor mat 
2. Exertion is recorded using 
pulse oximetry and a capnograph 
RPE= Rate of Perceived Exertion; FR= Functional Reach 
Table 3.2 Assessment session timeline 
 
To minimise the risk of harm, the exertional walking task could be self-terminated if the participant 
felt they were no longer able to participate in the assessment.  The walking task could also be ended 
at the determination of the data collector (a registered Physiotherapist).  Reasons for termination 
include a near-miss fall, an unsafe or increasingly unstable gait, a change in observational measures 
of exertion outside of acceptable levels, or a change in the level of cognition of the participant.  All 
uncompleted assessments were accompanied by a description of why the test was terminated.   
 
Setting 
The study was conducted at the University of Tasmania Exercise Physiology Clinic located on the 
Newnham Campus in Northern Tasmania, Australia.  Participants in the study were recruited from 
Pulmonary Rehabilitation Groups operating at the same venue.  Data collection occurred at this site 
to ensure participants had accessibility to the venue and to utilise equipment available in the 
controlled environment of the Exercise Physiology Clinic.  The study was carried out under the 
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supervision of a Physiotherapist, an Exercise Physiologist, and an assistant, to ensure adequate 
supervision, and for maintenance of data integrity.   
 
Participants 
Participants were comprised of current or recent attendees of Pulmonary Rehabilitation (at the 
University of Tasmania, Newnham Campus).  Only adults (over the age of 18 years) with a confirmed 
diagnosis of COPD (and GOLD classification using spirometry) were included in the study.  
Participants must be able to provide informed consent to participate in the study, ambulate 
independently on a flat even surface (to complete the test safely), and live at home (with or without 
oxygen supplementation).   
 
People excluded from the study were those who have end-stage COPD requiring palliative 
management, or people with a self-reported acute infective exacerbation in their symptoms.  People 
that require a gait aid, a prosthetic limb, or physical assistance to walk were also excluded from the 
study to enable clean data capture on a gait sensor mat and reduce the interference of a gait aid 
augmenting gait stability.  Other exclusions include people with a significant neurological condition 
affecting their gait regularity, and pregnant females.   
 
Sample size and justification 
As this is the first study to examine changes in gait variability and balance during exertional tasks in 
people with COPD, a clinically relevant sample size of 20 had been selected.  We have not been able 
to identify any literature reporting changes in gait variability and balance during exertional tasks in 
any other clinical or non-clinical population.  Therefore, this project is pilot work to determine the 
feasibility and number of participants required for a larger comparative study.   
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Recruitment 
Recruitment targeted participants of the Pulmonary Rehabilitation program operating at the 
University of Tasmania (Newnham Campus) using a recruitment poster.  The poster had an invitation 
to participate in the study, outlined what the study involved, and offered an invitation to attend an 
information session.  Those expressing an interest to attend the information session recorded their 
contact details on a sign-up sheet or contacted the researcher directly to have their enrolment 
recorded.   
 
People attending the information session received a participant information sheet.  During the 
information session, the researcher (who was not their treating clinician) outlined the procedure 
involved in the study, explained the inclusion and exclusion criteria, and invited those consenting to 
be involved in the study to indicate their informed consent by signing a consent form.  Participants 
were informed that they would not be disadvantaged if they chose not to participate in the study.   
 
Measures 
Participant descriptive data was collected in an interview and included Sex, date of birth, length of 
time from diagnosis of COPD, relevant past medical history, smoking history, medications (including 
supplementary oxygen), and self-reported weekly activity habits.   
 
Height and weight measurements were taken using a wall-mounted tape measure and floor scales.  
A lung function test was taken using a spirometer (COSMED Pony FX).  Spirometry measures 
included: Forced Vital Capacity (FVC) – the total volume of air that the patient can forcibly exhale in 
one breath; Forced Expiratory Volume in 1 second (FEV1) – the volume of air that the patient can 
exhale in the first second of forced expiration; and the ratio of FEV1 to FVC (FEV1/FVC).  This data can 
be compared to normative data and be used to calculate COPD severity using the Global Initiative for 
Chronic Obstructive Lung Disease Spirometry Criteria for COPD (Vestbo et al. 2013).  During 
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Spirometry testing, participants were instructed to take a breath-in until the lungs feel full, hold their 
breath long enough to seal their lips tightly around the mouthpiece, then blast the air out as forcibly 
and fast as possible until there is no more air left.   
 
Two validated tools for measuring exertional walking were utilised, the 6MWT and the ISWT.  The 
6MWT is a submaximal test with normative data developed for community-dwelling older adults 
(Steffen, Hacker & Mollinger 2002) and it is used as a performance measure of gait endurance 
(Guyatt et al. 1985).  Two tests within 30 minutes are required for validity.  The object of this test is 
to walk as quickly as possible for six minutes between two markers, so that the participant can cover 
as much ground as possible.  The participant may slow down if necessary or stop.  The participant 
may recommence walking again as soon as possible, until the full six-minute duration has elapsed.   
 
The ISWT is a standardised externally-paced incremental field walking task that provokes a symptom-
limited maximal performance (Singh et al. 1992).  It is used to assess functional capacity in people 
with chronic airways obstruction.  One test is required for learning; a repeat test is then performed 
for assessment.  The participant is required to walk between two cones, set nine metres apart, in 
time to a set of auditory beeps played on a CD.  Initially, the walking speed is very slow, but each 
minute the required walking speed progressively increases.  The participant walks until they are 
either too breathless or can no longer keep up with the beeps, at which time the test ends.   
 
Outcome Measures 
Dynamic Balance is measured using Functional Reach Test (FR).  FR test is a performance measure 
which identifies the ability to reach forward in bilateral stance (self-generated perturbation) (Duncan 
et al. 1990).  The functional reach test can be performed quickly and safely and unlike other more 
robust measures of balance, in this context, can be applied to capture transient changes in balance 
control before elevated exertion levels return to baseline readings.  This measure is performed 
before and after each intervention to identify a change in the dynamic balance after exertional 
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walking.  The participant is instructed to stand next to, but not touching, a wall and position the arm 
that is closer to the wall, at 90 degrees of shoulder flexion, with a closed fist.  The assessor will 
record the starting position at the 3rd metacarpal head on the yardstick.  The participant is then 
instructed to “reach as far as you can forward without taking a step.”  The finishing position of the 
third metacarpal is then recorded.  Scores are determined by assessing the difference between the 
start and end position is the reach distance (cm).   
 
Gait regularity is assessed on an 8-meter GAITRite mat using GAITRite analysis software 
(Manufactured by CIR Systems, Inc., 12 Cork Hill Road, Building #2, Franklin, NJ 07416, United States 
of America).  GAITRite analysis is a valid and reliable tool for measuring selected spatial and temporal 
parameters of gait (McDonough et al. 2001).   
 
Double support time, step length, and support base standard deviation were analysed for differences 
between the first two passes of the gait sensor when exertion levels are low, and the last two passes 
of the sensor mat when exertion levels are elevated.  These gait variables are commonly used in gait 
assessment and are recognised as independent predictors of falls in older adults (Nantsupawat et al. 
2015; Verghese et al. 2009).  The standard deviation of stance time, stride time, and swing time are 
spatiotemporal gait measures with demonstrated ability to discriminate between fallers and non-
fallers in both people with COPD and healthy older adults (Marques et al. 2017; Marques et al. 2018).  
Variability (using standard deviation) in these gait parameters was used to analyse change from the 
beginning to the end of the walk tests and observe change during the walk tests.   
 
Physical exertion is measured using Heart Rate (HR), Respiratory Rate (RR), Peripheral Oxygen 
Saturation (SpO2), and End-tidal Carbon Dioxide (ETCO2) continuously during the walking tasks.  
These measures were collected using Capnography and Pulse Oximetry (data captured using a 
Nellcor™ N-85 handheld Capnograph/Pulse Oximeter calibrated and distributed by Medtronic 
Australasia Pty Ltd., 5 Alma Road, Macquarie Park NSW 2113, PO Box 945, North Ryde NSW 1670, 
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Australia).  A Pulse Oximeter is a non-invasive lightweight device that clips onto the finger and 
displays the calculated oxygen saturation percentage, and will display heart rate (DeMeulenaere 
2007).  Capnography is a non-invasive method of monitoring respiration and can be used to record 
RR and ETCO2 levels (Casey 2015).   
 
Perceived exertion is recorded using the Modified Borg Dyspnoea Scale.  The dyspnoea scale is a 
10-point self-rated perception of shortness of breath commonly used during the 6MWT as an 
indicator of exertion (Ries 2005).  The Modified Borg Dyspnoea Scale measure is taken before the 
task, at 30-second intervals during the task, and on completion of each exertional task.   
 
Data Collection and Analysis 
A Consort Flow Diagram is utilised to standardise data collection processes.  Numbers of potential 
participants screened and those who meet the inclusion criteria were recorded, with any excluded 
participants along with the reasons for exclusion recorded using the consort flow diagram (Figure 
3.3).   
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Figure 3.1 Study rationale and design consort flow diagram 
 
Assessed for eligibility (n=22) 
Excluded (n=1) 
Not meeting inclusion 
criteria (n=1) 
Declined to participate (n=0) 
Analysed: (n=11) 
▪ Excluded from analysis (n=0) 
 
Crossover test: ISWT  
▪ Completed test (n=11) 
▪ Did not complete test (n=0) 
6 Minute Walk Test (n=11) 
▪ Completed test (n=11) 






assessment (n = 20) 
 
Shuttle Walk Test (n=9) 
▪ Completed test (n=9) 
▪ Did not complete test (n=0) 
Crossover test: 6MWT 
▪ Completed test (n=9) 
▪ Did not complete test (n=0) 
(One participant completed 
only one walk test due to a 
near miss fall in the first walk 
tests) 
Analysed: (n=9) 
▪ Excluded from analysis (n=0) 
(For the participant that only 
completed one 6 Minute Walk 
Test their test was included in 
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Data collection was undertaken with a minimum of two trained supervisors to ensure the safety of 
the people participating in the study and adherence to data collection protocol.  Standardisation of 
assessment processes to ensure inter-test assessment reliability included the correct application of 
standardised tests and consistency of environment, e.g. shoes on or off, lead-in walking distance for 
capturing gait analysis.  Additionally, tests for the same person were repeated near the same time of 
day between visit two and three, and activity levels and eating patterns prior to assessment were 
standardised and monitored.  Deviations from the data collection process including adverse events 
or failure to complete the assessment were recorded and documented appropriately.  Records were 
stored both in hard copy and electronically in a secure manner and retained securely for a standard 
period.   
 
Data manipulation and statistical analyses 
The impact of exertional walking on gait regularity is analysed using mixed-effects linear regression 
modelling for within-task and between task comparisons using R Studio, R version 3.3.3 (2017-03-
06).  Data was tested for normality in distribution and is presented as mean and standard deviation 
with 95% confidence intervals.  Cohen’s d statistic ('Statistical Power Analysis for the Behavioral-
Sciences - Cohen,J'  1988) was used to analyse the effect size for the difference between the start-
test and end-test means for gait variables.  The effect size was categorised as small (≤ .2), medium (.2 
to .5), or large (≥ .8). 
 
Paired t-test between the start and end of exertional walking tests is used to assess the impact of 
exertional walking on gait variability and dynamic balance is measured by functional reach.  Averages 
of the first two passes were taken as the ‘start test’ reading and the last two passes were taken as 
the ‘end test’ reading.  Start and end-test comparisons are analysed in exertional walking stance 
time, swing time, double support time, step length, and support base standard deviation.  FR was 
measured directly before (within 1 minute) and immediately (less than 30 seconds) following the 
exertional walk test.  
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Standard deviation is selected to measure variability of gait parameters as it is a common measure of 
fluctuations in stride to stride pattern, and stance time standard deviation has been demonstrated to 
have the greatest sensitivity and specificity to discriminate between fallers and non-falling older 
adults (Marques et al. 2017; Marques et al. 2018).  Correlation coefficient using a Pearson's product-
moment correlation (r value) with a corresponding p value and 95% confidence intervals is used to 
express the strength and direction of the linear relationship between the standard deviation of each 
gait variable and time, as well as for changes to gait regularity (stance, stride, and swing time 
standard deviation) and measures of exertion (rate of perceived exertion, oxygen saturation, end-
tidal carbon dioxide level, respiratory rate, and heart rate).  
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CHAPTER 4  
Results  
Distribution of data 
All data analysed were normally distributed and where appropriate is presented as mean and 
standard deviation.  
 
Demographic Data 
The number of participants was 20, comprising of 17 females and 3 males.  Participant age ranged 
from 54 years to 83 years with a mean age of 70.8 (± 8.2) years (Table 4.1).  Forced Expiratory 
Volume (FEV1), Forced Vital Capacity (% FVC) mean was 63.7 (±17.5).  The median Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) ranking was 2 (Moderate).  Of the participants, 3 had a 
GOLD ranking mild, 12 were moderate, 4 were severe, and 1 was very severe.  The average Body 
Mass Index (BMI) was 28.0 (±5.2) kg/m2.  Polypharmacy was present in 65% of participants with the 
mean number of medications 7 (±7) (Table 4.1 and Table 4.2).  Only one participant was on home 
oxygen and completed the walk test with oxygen running at 3 L/min (usual rate), using a portable 
oxygen concentrator unit and delivered via nasal prongs.   
 
Table 4.1 Participant Demographics 
Measure n Mean (SD) Min Max 
Age (Years) 20 70.8 (±8.2) 54 83 
FEV1 (%FVC) 20 63.7 (±17.5) 26.1 92.1 
GOLD Ranking 20 2.2 (±0.7) 1 4 
BMI (kg/m2) 20 26.5 (±5.2) 17.3 38.2 
Number of Medication/s 20 7 (±5) 0 18 
Number of Respiratory infections / Year 20 1 (±1) 0 5 
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Table 4.2 Polypharmacy (≥5 medications) Incidence and Home Oxygen use 
 n Yes (%) No (%) 
Polypharmacy 20 13 (65%) 7 (35%) 
Home Oxygen 20 1 (5%) 19 (95%) 
 
The mean number of passes completed in the 6MWT was 19 (±5) (Table 4.3).  In the ISWT, the mean 
number of passes was 29.1 (±7) and the mean test conclusion time was 359.5 seconds (±68.94). 
 
Table 4.3 Distance Covered in Walk Tests 
Test n Measure Mean (SD) Min Max 
6MWT 19 
Passes (25 m track) 19 (±5) 14 36 
Distance (m) 482 (±121) 350 900 
Time (sec) 360 (±0) 360 360 
ISWT 20 
Passes (10 m track) 29.1 (±7) 18 39 
Distance (m) 291 (±67) 180 390 
Time (sec) 359.5 (±68.94) 230 480 
 
Adverse events 
One participant completed both ISWTs but only one 6MWT.  That person, under supervision, was 
observed to have a near miss fall (without injury) near the end of the first 6MWT, was deemed at risk 
of falling, and dissuaded from completing the repeat 6MWT.  The participant was not on oxygen, was 
GOLD ranking 1, had not reported a falls history or recent acute exacerbation of COPD, and had a 
bronchiectasis type presentation of COPD. Data collected in that participant’s first 6MWT was used 
in the data analysis.  All other participants completed all the walk tests without adverse events.   
 
Gait variability over time  
Gait variables were measured at the first two passes of the sensor mat (named start-test) and over 
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Stance time standard deviation  
Stance time is the duration (sec) one limb spends in contact with the ground from the heel first 
contacting the surface to the time the toes lift from the ground.   
 
Stance time standard deviation in the 6MWT for the left side and right side had a start-test mean of 
0.01 seconds (±0.01) and 0.01 (±0.01), respectively.  Stance time standard deviation for the 6MWT 
measured at the last two passes of the sensor mat for the left side and right side was also 0.01 
seconds (±0.01) and 0.01 (±0.01), respectively.  A paired Cohen’s d analysis showed a statistically 
small effect size in the stance time standard deviation from start to the end-test d= .06 (95%CI: .01 to 
.14) for the left side and d= .15 (95%CI: .07 to .22) on the right in the 6MWT.  A paired t-test (two 
sided) analysis demonstrated no significant change from start to end-test stance time standard 
deviation in the 6MWT for the left p= .779 (95%CI: -0.003 to 0.003) or right p= .939 (95%CI: -0.003 to 
0.003) (Figure 4.1a).   
 
Stance time standard deviation in the ISWT had a start-test mean for the left and right of 0.01 
seconds (±0.01) and 0.01 seconds (±0.01), respectively.  End-test mean in stance time standard 
deviation for the ISWT left and right was 0.02 seconds (±0.02) and 0.01 (±0.01), respectively.  In the 
ISMWT the effect size from the start to the end-test mean was statistically small with d= - .02 (95%CI: 
- .09 to .05) for the left and d= - .13 (95%CI: - .20 to - .06) on the right side.  There was no significant 
change in ISWT start to end-test stance time standard deviation p= .398 (95%CI: -0.006 to 0.002) for 
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Box and Whisker plot showing the interquartile distribution 




Box and Whisker plot showing the interquartile distribution 
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There was no association between left leg stance time standard deviation and time, for either the 
6MWT (r= .069, p= .19) or the ISWT (r= .026, p= .51) (Figure 4.1c).  
 
Linear regression plot displaying mean and 95%CI 
Figure 4.1c Left Stance Time Standard Deviation Over Time 
 
There was no association between right stance time standard deviation and time, for either the 
6MWT (r= .046, p= .38) or the ISWT (r= .016, p= .68) (Figure 4.1d). 
 
Linear regression plot displaying mean and 95% CI 
Figure 4.1d Right Stance Time Standard Deviation Over Time 
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Stride time standard deviation  
Stride time is the duration between the first contact with the ground of two consecutive footsteps of 
the same foot. 
 
Stride time standard deviation in the 6MWT for the left and right side had a start-test mean of 0.01 
seconds (±0.01) and 0.01 (±0.01), respectively.  Stride time standard deviation for the 6MWT 
measured at the last two passes of the sensor mat for the left and right was 0.01 seconds (±0.01) and 
0.02 (±0.01), respectively.  Cohen’s d analysis showed a statistically small effect size from the start to 
the end-test mean of d= .01 (95%CI: - .07 to .08) on the left side and d= .09 (95%CI: .02 to .16) on the 
right-side.  A paired t-test (two sides) analysis demonstrated no significant change from start to end-
test stride time standard deviation in the 6MWT for the left side p= .980 (95%CI: -0.003 to 0.003) or 
right-side p= .575 (95%CI: -0.006 to 0.003) (Figure 4.2a).   
 
Stride time standard deviation in the ISWT had a start-test mean on the left and right side of 0.02 
seconds (±0.01) and 0.01 (±0.01), respectively.  End-test mean in stride time standard deviation for 
the ISWT on the left and right side was 0.02 seconds (±0.02) and 0.02 seconds (±0.01), respectively.  
A statistically small effect size of d= .07 (95%CI:  .00 to .14) was observed on the left and d= - .07 
(95%CI: - .14 to .00) on the right-side.  There was no significant change in ISWT start to end-test 
stride time standard deviation p= .815 (95%CI: -0.004 to 0.003) for the left side, and p= .875 (95%CI: -
0.005 to 0.006) on the right side (Figure 4.2b).   
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Box and Whisker plot showing the interquartile distribution 




Box and Whisker plot showing the interquartile distribution 
Figure 4.2b Right Stride Time Standard Deviation (seconds) at Start and End-test for 6MWT and 
ISWT 
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There was no association between left leg stride time standard deviation and time, for either the 
6MWT (r= .072, p= .17) or the ISWT (r= .035, p= .38) (Figure 4.2c).  
 
Linear regression displaying mean and 95% CI 
Figure 4.2c Left Stride Time Standard Deviation Over Time 
 
There was no association between gait variability measured as right stride time standard deviation 
and time, for either the 6MWT (r= .075, p= .16) or the ISWT (r= .044, p= .27) (Figure 4.2d). 
 
Linear regression displaying mean and 95% CI 
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Swing time standard deviation  
Swing time is the duration in which the swinging foot is not in contact with the ground and is 
travelling from point of contact to point of contact. 
 
Swing time standard deviation in the 6MWT on the left and right side had a start-test mean of 0.01 
seconds (±0.00) and 0.01 (±0.01), respectively.  The mean swing time standard deviation for the 
6MWT measured at the last two passes of the sensor mat for the left and right was 0.01 seconds 
(±0.00) and 0.01 (±0.01), respectively.  Cohen’s d analysis showed a statistically small effect size from 
the start to the end-test mean of d= .08 (95%CI: - .15 to - .01) on the left side but bordering on a 
moderate effect size of d= - .23 (95%CI: - .30 to - .15) on the right-side.  A paired t-test (two sided) 
analysis demonstrated no significant change from start to end-test swing time standard deviation in 
the 6MWT on the left side p = 0.751 (95%CI: -0.002 to 0.002) or right-side p= .357 (95%CI: -0.001 to 
0.003) (Figure 4.3a).   
 
Swing time standard deviation in the ISWT had a start-test mean on the left and right side of 0.01 
seconds (±0.01) and 0.01 (± 0.00), respectively.  End-test mean in swing time standard deviation for 
the ISWT left and right side was 0.01 seconds (±0.00) and 0.01 (±0.00), respectively.  A statistically 
small effect size of d= .09 (95%CI:  .02 to .16) was observed on the left and right-side d= .03 (95%CI: - 
.04 to .10).  There was no significant change in ISWT start to end-test swing time standard deviation 
p = 0.686 (95%CI: -0.002 to 0.001) for the left side, and p= .907 (95%CI, -0.002 to 0.002) on the right 
side (Figure 4.3b).   
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Box and Whisker plot showing the interquartile distribution 




Box and Whisker plot showing the interquartile distribution 
Figure 4.3b Right Swing Time Standard Deviation (seconds) at Start and End-test for 6MWT and 
ISWT 
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There was no association between gait variability measured as left leg swing time standard deviation 
and time, for either the 6MWT (r= .059, p= .27) or the ISWT (r= .017, p= .67) (Figure 4.3c).  
 
Linear regression displaying mean and 95% CI 
Figure 4.3c Left Swing Time Standard Deviation Over Time 
 
There was a small but statistically significant association between right leg swing time standard 
deviation and time for the ISWT (r= .11, p= .0067) but not the 6MWT (r= .013, p= .8) (Figure 4.3d). 
 
Linear regression displaying mean and 95% CI 
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Double support time standard deviation  
Double support time is the duration of time both feet are in contact with the ground and was 
measured in seconds.   
 
Double support time standard deviation in the 6MWT for the left and right side had a start-test mean 
of 0.01 seconds (±0.01) and 0.01 (±0.01), respectively.  The mean of the last two passes of the sensor 
mat for the left and right side was 0.01 seconds (±0.00) and 0.01 (±0.00), respectively (Figure 4.4a).  
Cohen’s d analysis showed a statistically small effect size from the start to the end-test mean of d= 
.05 (95%CI: - .02 to .12) on the left side but a moderate effect size of d= .30 (95%CI: .22 to .38) on the 
right-side.  A paired t-test (two sided) analysis demonstrated no significant change from start to end-
test double support time standard deviation in the 6MWT for the left side p= .797 (95%CI: -0.003 to 
0.002) or right-side p= .097 (95%CI: -0.004 to 0.000).   
 
Double support time standard deviation in the ISWT had a start-test mean for the left and right side 
of 0.01 seconds (±0.01) and 0.01 (±0.01), respectively.  End-test mean in double support time 
standard deviation for the ISWT left and right side was 0.01 seconds (±0.00) and 0.02 (±0.01), 
respectively.  A statistically small effect size of d= .00 (95%CI: - .07 to .07) was observed on the left 
and a borderline moderate effect size of d= - .20 (95%CI: - .27 to - .13) on the right-side.  There was 
no significant change in ISWT start to end-test double support time standard deviation p= .995 
(95%CI: -0.003 to 0.002) for the left side, and p= .552 (95%CI, -0.002 to 0.003) on the right side 
(Figure 4.4b).   
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Box and Whisker plot showing the interquartile distribution 
Figure 4.4a Left Double Support Time Standard Deviation (seconds) at Start and End-test for 
6MWT and ISWT 
 
 
Box and Whisker plot showing the interquartile distribution 
Figure 4.4b Right Double Support Time Standard Deviation (seconds) at Start and End-test for 
6MWT and ISWT 
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There was no association between left leg double support time standard deviation and time, for 
either the 6MWT (r= .037, p= .48) or the ISWT (r= .034, p= .39) (Figure 4.4c).  
 
Linear regression displaying mean and 95% CI 
Figure 4.4c Left Double Support Time Standard Deviation Over Time 
 
There was a small but statistically significant association between right-side double support time 
standard deviation and time for the ISWT (r= .11, p= .0077) but not the 6MWT (r= .024, p= .65) 
(Figure 4.4d). 
 
Linear regression displaying mean and 95% CI 
Figure 4.4d Right Double Support Time Standard Deviation Over Time 
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Step length standard deviation  
Step length is the longitudinal distance from the heel contacting with the ground of one foot to the 
heel contacting the ground in the alternate foot.   
 
In the 6MWT for the left side, there was no statistically significant change in the step length standard 
deviation from the start-test mean of 1.93 (±1.09) to the end-test mean of 1.40 cm (±0.73) p= .960 
(95%CI, -0.353 to 0.335) (Figure 4.5a).  Similarly, there was no statistically significant change for the 
right-side step length standard deviation from start-test mean 1.63 cm (±1.07) to end-test mean 1.44 
cm (±0.91) p= .421 (95%CI: -0.492 to 0.207) (Figure 4.5b).  Cohen’s d analysis showed a statistically 
small effect size from the start to the end-test mean of d= .01 (95%CI: - .06 to .08) on the left side 
and d= .18 (95%CI: .11 to .26) on the right-side.   
 
In the ISWT for the left side, there was no statistically significant change in the step length standard 
deviation from the start-test mean of 1.98 (±1.04) cm to the end-test mean of 2.01 cm (±0.70) p= 
.307 (95%CI: -0.159 to 0.501) (Figure 4.5a).  Similarly, there was no statistically significant change for 
the right-side step length standard deviation from start-test mean of 1.73 cm (±1.07) to end-test 2.14 
cm (± 1.06) (p= .949; 95%CI: -0.348 to 0.326) (Figure 4.5b).  A statistically borderline but moderate 
effect size of d= - .25 (95%CI: - .33 to - .18) was observed on the left and a small effect size of d= .02 
(95%CI: - .05 to .09) on the right-side.   
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Box and Whisker plot showing the interquartile distribution 
Figure 4.5a Left Step Length Standard Deviation (cm) at Start-Test and End-Test 
 
 
Box and Whisker plot showing the interquartile distribution 
Figure 4.5b Right Step Length Standard Deviation (cm) at Start-Test and End-Test 
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There was no association between left step length standard deviation and time, for either the 6MWT 
(r= .095, p= .074) or the ISWT (r= .054, p= .18) (Figure 4.5c).  
 
Linear regression displaying mean and 95% CI 
Figure 4.5c Left Step Length Standard Deviation Over Time 
 
There was no association between right step length standard deviation and time, for either the 
6MWT (r= .056, p= .29) or the ISWT (r= .041, p= .31) (Figure 4.5d).  
 
Linear regression displaying mean and 95% CI 
Figure 4.5d Right Step Length Standard Deviation Over Time 
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Support base standard deviation 
The support base is measured as the horizontal width between footfalls at the phase in the gait cycle 
where both feet are in contact with the ground, measured in centimetres.   
 
Support base standard deviation in the 6MWT had a start-test mean of 1.46 (± 0.88) cm on the left 
side and of 2.02 (±1.04) cm on the right side.  End-test support base standard deviation for the 
6MWT was 1.94 (± 1.10) cm on the left side and 2.13 (±1.09) cm on the right side (Figure 4.6a and 
Figure 4.6b, respectively).  Cohen’s d analysis showed a statistically small effect size from the start to 
the end-test mean of d= .16 (95%CI: .09 to .24) on the left side and d= .13 (95%CI: .06 to .21) on the 
right-side.  Start to end test analysis (double-sided t-test) gave no significant change in support base 
standard deviation in the 6MWT on the left side p = 0.671 (95%CI: -0.438 to 0.283) or right-side p= 
.526 (95%CI: -0.516 to 0.265).   
 
Support base standard deviation in the ISWT had a start test mean of 2.13 (±0.94) cm on the left side 
and 2.26 (±1.10) cm on the right side.  End-test support base standard deviation mean for the ISWT 
was 2.36 (± 0.68) cm on the left side and 2.62 (± 1.01) cm on the right side.  There was no significant 
change in ISWT start to end-test support base standard deviation distance p= .367 (95%CI: -0.486 to 
0.181) for the left side and p= .847 (95%CI: -0.427 to 0.351) on the right side.  A statistically small 
effect size of d= .18 (95%CI:  .11 to .25) was observed on the left and d= .04 (95%CI: - .02 to .11) on 
the right-side.    
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Box and Whisker plot showing the interquartile distribution 
Figure 4.6a Left Support Base Standard Deviation (cm) at Start and End-Test 
 
 
Box and Whisker plot showing the interquartile distribution 
Figure 4.6b Right Support Base Standard Deviation (cm)at Start and End-Test 
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There was no association between left side support base standard deviation and time, for either the 
6MWT (r= .036, p= .5) or the ISWT (r= .03, p= .45) (Figure 4.6c).  
 
Linear regression displaying mean and 95% CI 
Figure 4. 6c Left Support Base Standard Deviation Over Time 
 
There was a small but statistically significant association between right-side support base standard 
deviation and time, for the ISWT (r= .11, p= .0077) but not the 6MWT (r= .024, p= .65) (Figure 4.6d). 
 
Linear regression displaying mean and 95% CI 
Figure 4.6d Right Support Base Standard Deviation Over Time 
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Walking velocity by time 
In the 6MWT mean walking velocity was 144.9 cm/s (±18.1) with a range of 93.4 to 181.6 cm/s.  
Walking velocity was mostly constant, with a gradual reduction over the duration of the test (Figure 
4.7).  A Pearson's product-moment correlation coefficient of velocity over time was r= -.1, but this 
small negative association was not statistically significant (p= .18).  For the ISWT, mean walking 
velocity was 156.4 cm/s (±18.8) with a range of 92.8 to 213.3 cm/s.  In the ISWT, walking velocity 
increases with time, A Pearson's product/moment correlation coefficient of velocity over time was r= 
.4, and this positive association was statistically significant (p= ≤.001) (Figure 4.7).   
 
Linear regression displaying mean and 95% CI 
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Exertion by time 
In the 6MWT, all measures of exertion increased over time (Figure 4.8).  All measures except End 
Tidal Carbon Dioxide (ETCO2) changed significantly from start to end-test (Figures 4.8a-e).  Rate of 
Perceived Exertion (RPE) had a significant increase from mean 0.5 (±0.9) start-test to 4.3 (±1.6) post-
test, p= .002 (95%CI: -2.21 to -0.52) (Figure 4.8a).  Oxygen Saturation (SpO2) decreased (indicating 
increased exertion) significantly from a mean of 95.5% (±2.2) to 92.2% (±4.6), p= .010 (95%CI: 0.49 to 
3.46) (Figure 4.8b).  This level of reduced SpO2 may not be clinically significant in this population.  
ETCO2 increased from 33.6 mmHg (±4) to 35.9 mmHg (±4.2) but failed to reach statistical significance 
p= .139 (95%CI: -2.89 to 0.41) (Figure 4.8c).  Respiratory Rate (RR) significantly increased from a 
mean of 23.6 resp/min (±5.3) to 28.9 resp/min (±6.6), p= .006 (95%CI: -6.42 to -1.08) (Figure 4.8d).  
Heart Rate (HR) significantly increased from a mean of 92 BPM (±15.3) to 124 BPM (±17.5), p=0.004 
(95%CI: -21.1 to -4.14) (Figure 4.8e).   
 
In the ISWT, all measures of exertion increased over time (Figure 4.8), however from start- to end-
test only two of the five measures (RPE and HR) reached statistical significance (Figure 4.8a-e).  RPE 
increased significantly from mean 0.6 (±0.7) pre- to 4.6 (±2.2) post-test, p= .007 (95%CI: =-2.1 to -
0.34) (Figure 4.8a).  SpO2 reduced (indicating increased exertion) from a mean of 95.9 % (±2.2) % to 
90.7 (±4.3), p= .207 (95%CI: -0.56 to 2.54) (Figure 4.8b).  ETCO2 increased from 32.9 mmHg (±3.2) to 
36.5 mmHg (±6) but failed to reach statistical significance p= .400 (95%CI: -2.5 to 1.00) (Figure 4.8c).  
The RR increased from a mean of 21.8 resp/min (±5.2) to 32.7 resp/min (±9.1).  The increase may 
have clinical significance but failed to reach statistical significance p= .261 (95%CI: -4.76 to 1.31) 
(Figure 4.8d).  HR significantly increased from a mean of 90 BPM (±15.3) to 123.4 BPM (±15.8), p= 
.034 (95%CI: -17.56 to -0.69) (Figure 4.8e).   
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Linear regression displaying mean and 95%CI 






Exertion Parameters Over Time by Walk-Test Type 
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*Significantly different from baseline values (p≤.05) 
Method: Paired t-test (two sides) 
Figure 4.8a Start and End Mean RPE by Walk-Test Type 
 
 
*Significantly different from baseline values (p≤.05) 
Method: Paired t-test (two sides) 
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*Significantly different from baseline values (p≤.05) 
Method: Paired t-test (two sides) 
Figure 4.8c Start and End Mean ETCO2 by Walk-Test Type 
 
*Significantly different from baseline values (p≤.05) 
Method: Paired t-test (two sides) 
























































Start and End-Test Respiratory Rate (+/- 1 SD)
* 
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*Significantly different from baseline values (p≤.05) 
Method: Paired t-test (two sides) 







































Start and End-Test Heart Rate (+/- 1 SD)
* * 
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Dynamic balance pre and post-test 
In the 6MWT pre-test Functional Reach (FR) mean distance was 30.08 cm (±6.15) and a post-test FR 
mean was 29.95 cm (± 5.08).  A paired t-test (two sided) on pre- to post-test FR demonstrated no 
significant change in reach distance p= .860 (95%CI: -1.34 to 1.59) (Figure 4.9).  Similar results were 
evident for the ISWT.  Pre-test FR mean was 30.88 cm (±5.95) and post-test FR mean was 30.23 cm 
(±5.51).  Pre-post FR analysis for the ISWT demonstrated no significant change in reach distance p= 
.463 (95%CI: -1.17 to 2.47). 
 
Box and whisker plot showing mean and inter-quartile distribution 
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Gait variability by exertion  
Stance time standard deviation 
Stance time standard deviation in the 6MWT had a small negative association, approaching 
significance with ETCO2 (r= -.103, p= .053, 95%CI: -0.206 to 0.002) on the right site and a significant 
association with HR on the left side (r= -.143, p= .016, 95%CI: -0.257 to -0.027) (Table 4.4).  No other 
significant associations with measures of exertion were observed for stance time standard deviation 
in the 6MWT.  Stance time standard deviation in the ISWT had no significant association with 
measures of exertion except for RPE, which had a positive association of r= .133, p= .049 (95%CI: 
0.001 to 0.262).   
 
Table 4.4 Stance Time Standard Deviation versus Exertion Correlation Coefficient 
 Left Side Right Side 
Walk 
Test 
Exertion r. value p. value 95%CI r. value p. value 95%CI 
6MWT 
RPE .055 .525 -0.115 0.223 -.031 .724 -0.199 0.140 
ETCO2 -.103 .053 -0.206 0.002 .019 .719 -0.086 0.124 
SpO2 .084 .162 -0.034 0.199 -.024 .690 -0.141 0.094 
RR -.001 .987 -0.106 0.104 -.014 .796 -0.119 0.091 
HR .020 .737 -0.097 0.137 -.143 .016* -0.257 -0.027 
ISWT 
RPE .072 .289 -0.061 0.203 .133 .049* 0.001 0.262 
ETCO2 .052 .205 -0.028 0.131 .074 .071 -0.006 0.153 
SpO2 .022 .598 -0.060 0.104 -.056 .182 -0.138 0.026 
RR -.011 .781 -0.092 0.069 -.024 .565 -0.104 0.057 
HR .060 .151 -0.022 0.142 .069 .099 -0.013 0.151 
Method: Pearson's product-moment correlation.  Alternative: two sided 
* significant values (p≤.05) 
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Stride time standard deviation 
Stride time standard deviation had no significant linear relationship with measures of exertion for 
either the 6MWT or the ISWT on the left side (Table 4.5).  On the right side, stride time standard 
deviation had a significant negative association with HR r= -.164, p= .006 (95%CI, -0.276 to -0.047) in 
the 6MWT but not the ISWT, and a significant positive association with ETCO2 in the ISWT only r= 
.104, p= .011 (95%CI: 0.024 to 0.182).   
 
Table 4.5 Stride Time Standard Deviation versus Exertion Correlation Coefficient 
 Left Side Right Side 
Walk 
Test 
Exertion r. value p. value 95%CI r. value p. value 95%CI 
6MWT 
RPE .021 .814 -0.150 0.189 .030 .733 -0.141 0.198 
ETCO2 -.011 .838 -0.115 0.094 -.028 .599 -0.132 0.077 
SpO2 .001 .993 -0.117 0.118 .002 .979 -0.116 0.119 
RR -.024 .652 -0.129 0.081 .003 .954 -0.102 0.108 
HR .016 .785 -0.101 0.134 -.164 .006* -0.276 -0.047 
ISWT 
RPE .111 .102 -0.022 0.241 -.011 .877 -0.143 0.123 
ETCO2 -.009 .820 -0.089 0.071 .104 .011* 0.024 0.182 
SpO2 .025 .551 -0.057 0.107 .017 .685 -0.065 0.099 
RR .039 .347 -0.042 0.119 -.050 .220 -0.130 0.030 
HR .067 .109 -0.015 0.149 .051 .221 -0.031 0.133 
Method: Pearson's product-moment correlation.  Alternative: two sided 




Page | 84  
 
Swing time standard deviation 
Swing time standard deviation had no significant association with measures of exertion for the left or 
right side for either the 6MWT or ISWT (Table 4.6).  In summary, there was no clear observable linear 
association between left or right-side stride, stance, or swing time fluctuations and measures of 
exertion in either the 6MWT or ISWT, despite a clear statistically significant pattern of increasing 
exertion for both walk tests.  
 
Table 4.6 Swing Time Standard Deviation versus Exertion Correlation Coefficient 
 Left Side Right Side 
Walk 
Test 
Exertion r. value p. value 95%CI r. value p. value 95%CI 
6MWT 
RPE .088 .310 -0.082 0.254 .063 .470 -0.108 0.230 
ETCO2 .026 .621 -0.078 0.131 -.058 .279 -0.162 0.047 
SpO2 -.077 .200 -0.193 0.041 .058 .338 -0.060 0.174 
RR -.052 .336 -0.156 0.054 .048 .374 -0.057 0.152 
HR -.021 .727 -0.138 0.097 -.017 .771 -0.135 0.100 
ISWT 
RPE .114 .093 -0.019 0.243 -.009 .892 -0.142 0.124 
ETCO2 -.012 .767 -0.092 0.068 .041 .318 -0.039 0.121 
SpO2 .006 .886 -0.076 0.088 .013 .751 -0.069 0.096 
RR .012 .764 -0.068 0.093 -.027 .513 -0.107 0.054 
HR -.060 .156 -0.141 0.023 -.021 .625 -0.103 0.062 
Method: Pearson's product-moment correlation.  Alternative: two-sided 








The primary aim of this research was to determine if people with COPD are at an increased risk of 
falling during activities that require increased exertional effort.  Risk of falling in COPD as measured 
by gait variability did not change with exertion in either the 6MWT or ISWT.  Also, balance control 
did not change after completing either of these exertional walking tests.  Although participants 
demonstrated high levels of exertion, these results indicate participation in these exertional walking 
assessments does not increase the risk of accidental falls beyond baseline exertion levels.  As walking 
regularity does not degrade from baseline levels, this original research supports the continued use of 
either walking test in a community-dwelling COPD cohort. 
 
Primary aims 
Gait variability  
Stance time, double support time, and step length did not deteriorate from the start of the 
exertional walking tests to the end of the tests in this study.  These gait measures are validated falls 
risk predictors (Marques et al. 2018) and were chosen to comprehensively map the footfall pattern 
throughout the gait cycle.  As a single gait variable, stance time standard deviation has greater 
sensitivity and specificity to falls than gait speed, stride length, single limb support time, and double 
limb support time (Marques et al. 2018).  Marques et al. (2017) identified a cut-off value of 0.102 
seconds for stance time standard deviation (from heel strike to toe-off) to discriminate between 
fallers and non-falling older adults (sensitivity/specificity = 100/100%, p= ≤.001).  In this study, there 
was no increase in baseline levels of gait variability despite participants reaching maximum levels of 
exertion.  The hypothesis that as people with COPD increase their level of exertion during walking 
tasks, their gait regularity decreases is not supported.  This result indicates that the risk of sustaining 
an accidental fall does not further increase during exertional walking tests in the COPD population.   
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This research finding supports the ongoing use of exertional walking tests to measure the positive 
health benefits of pulmonary rehabilitation participation.  Until now, there was little evidence 
available to determine if walking with increased exertion during assessment increases gait variability 
and increases risk of falling.  Pulmonary rehabilitation by design increases exertion levels.  Both the 
6MWT and ISWT are regularly used in pulmonary rehabilitation and are accepted measures of 
exercise capacity (Brown & Wise 2007; Ho & Maa 2016).  Results from the present study 
demonstrate that participation in both tests (in a controlled environment) does not increase gait 
variability from baseline, nor does it increase the risk of accidental falls.  A possible mechanism 
behind this is that people are self-regulating their activity exertion levels to enable them to operate 
within a safe exercise tolerance boundary with respect to balance control.   
 
Dynamic balance 
Functional reach (FR) distance showed no significant change from pre-test when levels of exertion 
were low to post-test, when exertion levels were high, in either of the exertional walk tests.  This 
result indicates balance activities conducted in pulmonary rehabilitation in addition to exertional 
walking type activities are not likely to result in a reduction of balance control from baseline exertion 
levels.  The reach test was chosen as a self-generated perturbation measure of dynamic balance 
because it can be administered quickly while exertion levels are transiently elevated and for its utility 
as a predictor of recurrent falls (Duncan et al. 1992).  The hypothesis that dynamic balance 
deteriorates in response to exertional walking was not supported, further indicating that falls risk 
does not increase in this population as a result of participating in commonly used exertional walk 
tests. 
 
The current study indicates that balance control does not diminish as a result of increased exertion.  
This is surprising, because people with COPD have poor dynamic balance compared to healthy older 
adults (Beauchamp et al. 2012; De Castro et al. 2016; Voica et al. 2016) and high accidental falls rates 
(Hakamy et al. 2018; Sousa et al. 2017).  Until now, there was a sparsity of evidence available to 
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show that balance activities are safe during periods of elevated heart rate, respiratory rate, and rate 
of perceived exertion.  This has implications for including balance activities in pulmonary 
rehabilitation programs safely, as programs with a balance training component improve dynamic 
balance and reduce falls risk (Hill 2014; Marques et al. 2015; Mkacher et al. 2015).   
 
Secondary aims  
Relationship between gait regularity and exertion level  
There was no significant linear correlation between gait variation and changing levels of exertion 
throughout either the 6MWT or ISWT.  Stance, stride and swing time were used as measures of gait 
regularity because they are sensitive to differentiate between fallers and non-fallers (Marques et al. 
2018).  The 6MWT and ISWT were chosen as exertional walking tests, as they are the most 
commonly employed to provoke exertion (Ayiesah & Chang 2010; Brown & Wise 2007; Ho & Maa 
2016).  The hypothesis that there is an identifiable relationship between the level of exertion and 
gait regularity during exertional walking was not supported in the present study. 
 
Participants in the current study demonstrated the ability to self-regulate their exertion levels during 
effortful walking to prevent reductions in gait regularity.  This finding supports previous studies that 
show the 6MWT and ISWT to be associated with few fall events despite increasing exertional 
parameters such as exertion-induced oxygen desaturation (Afzal et al. 2018; Jenkins & Čečins 2011).  
Jenkins and Čečins (2011) identified that exercise induced oxygen desaturation (≥4% fall in SpO2 to < 
90%) to be prevalent (50%) in COPD during 6MWTs but with no reported accidental falls.  A similar 
study analysing records from a large pulmonary rehabilitation population found that desaturation 
even below SpO2 of 80%, was not associated with accidental falls (Afzal et al. 2018).  This study adds 
to the evidence that the high rate of falls in the COPD population may result from other factors than 
the reduction in circulating oxygen levels.  Some authors postulate that central nervous lesions from 
vascular abnormalities and not impaired respiratory function, may be responsible for increased fall 
rates in people with COPD (Morlino et al. 2017). 
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Gait variability and velocity 
Double support time, step length time, and support base standard deviation did not significantly 
change from pre- to post-test for either the 6MWT or the ISWT or in proportion to increasing velocity 
in the ISWT.  The ISWT had a linear increase in velocity with a significant change in pre- to post-test 
velocity (p= ≤ .001) whereas the 6MWT had a more uniform velocity with no statistically significant 
change throughout the tests.  Gait variability has been described as the most sensitive gait 
parameter to differentiate between fallers and non-falling older adults (Marques et al. 2018).  In the 
current study, no obvious pattern of change in gait variability occurred despite participants walking 
at their sustained maximum pace in the 6MWT or when walking at increasing velocities to the point 
of voluntary failure in the ISWT.  This clinically important result demonstrates that the risk of falling 
does not rise from baseline levels when self-governed incremental increases in gait velocity occur.   
 
Exertion – in the six-minute walk test and incremental shuttle walk test 
In the 6MWT, perceived rate of exertion, heart rate, and respiratory rate all increased significantly 
from start-test to end-test and oxygen saturation significantly dropped, but there was no significant 
change in end-tidal carbon dioxide levels.  The exertion profile was different for the ISWT as only 
perceived rate of exertion (RPE) and heart rate (HR) changed significantly from start-test to end-test 
readings.  For the exertion profile, RPE was selected as a self-rated measure of effort; the respiratory 
rate (RR) for ventilatory demand; heart rate (HR) as a measure of exercise intensity; oxygen 
saturation (SpO2) for aerobic capacity; and End-Tidal Carbon dioxide (ETCO2) for evidence of 
ventilatory compromise.  The 6MWT and the ISWT were chosen as exertional walking tests to 
analyse and contrast gait variability at sustained maximal exertion as well as at incrementally 
increasing levels of exertion to the point of voluntary failure.  Researchers in the present study 
selected the ISWT to analyse gait variability at maximum exertion and avoid the possibility that gait 
variables did not change due to an insufficient elevation in exertion.  It is clinically significant that gait 
regularity remained constant from start-test (low exertion) to end-test (self-governed maximal 
exertion).  This is because exertional walking tests commonly underpin assessment of functional 
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capacity (Andrianopoulos et al. 2015; Brown & Wise 2007; Ho & Maa 2016), guide intensity levels 
during pulmonary rehabilitation (Gloeckl, Marinov & Pitta 2013; Zainuldin, Mackey & Alison 2015), 
and are used as a predictor of disease prognosis (Celli et al. 2016; Dajczman et al. 2015).   
 
Exertional walk tests when used in the clinical management of COPD commonly measure SpO2, HR, 
and RPE.  Measurement of ETCO2 is less common in the sub-acute setting as it requires capnography 
equipment.  In this study, controlled steady-state walking during the 6MWT appeared to have less 
impact on RR and SpO2 than in the progressive ISWT.  The ISWT produced a larger range in RR and 
SpO2 than the 6MWT, but neither test resulted in exercise-induced hypercapnia.  ETCO2 levels 
increased in response to exertional walking but without statistical significance in either walk test.  
This result may indicate that the onset of hypercapnia has a larger impact on the perception of 
exertion and that participants reduced their intensity to prevent the onset of hypercapnia.  Despite 
the different exertion profiles between the walk tests, neither test observed a significant change in 
gait variability with self-governed exertion.  This result can be used to guide current management of 
people with moderate COPD, as it indicates that baseline level of falls risk does not change during 
exertional walking and that measurement of SpO2, HR, and RPE adequately give direction on safe 
intensity levels.   
 
Comparisons and contrasts to current literature  
Gait variability  
This was the first study to give a direct comparison of gait variations at different levels of exertion in 
a community-dwelling COPD cohort of mostly moderate severity.  The novel component of the 
present study was the direct comparison of gait variability in COPD measured at the beginning of a 
walk test (low-level exertion) to gait variability at the end of a walk test (high level of exertion).  The 
present study found no statistical difference in stride to stride fluctuations for stance time, double 
support time, and step length from the start of the walk tests to the end, meaning gait variability was 
unchanged from low-level exertion to the peak of self-governed high exertion.  Stance, double 
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support time, and step length variability have been validated as independent predictors of fallers in 
community-dwelling adults (Marques et al. 2018; Mignardot et al. 2014; Mortaza, Abu Osman & 
Mehdikhani 2014) but not measured in COPD at varying levels of exertion.  Currently, there is an 
absence in the literature of normative values for gait variability in COPD (Zago et al. 2018).  Most 
contemporary studies on gait variability in COPD give a comparison between COPD gait to healthy 
controls (Table 5.1) rather than in varying states of exertion.   
 
Table 5.1 Measures of gait variability found to be impaired in COPD  
Spatiotemporal gait variable  Finding Summary Study/s 
Step time variability 
• COPD had longer step time 
with shorter length (slower 
over ground velocity) than 
control participants 
• COPD had increased time 
between steps and more 
variable than control 
participants  
(Rutkowski et al. 2014; Yentes 
et al. 2017) 
Step width variability 
• COPD had reduced width 
and decreased variability 
compared to controls  
(Yentes et al. 2017; Yentes et al. 
2015) 
Step length variability 
• COPD had increased 
variability in step length 
compared to controls  
• Shorter step length than 
controls  
(Morlino et al. 2017; Rutkowski 
et al. 2014) 
Stride time variability 
• COPD had increased 
variability in stride time 
while dual tasking 
• COPD fallers had more 
variability than non-fallers 
• Stride time variability 
increased with COPD 
severity 
(Heraud et al. 2018; Lahousse 
et al. 2015; Liu et al. 2017) 
Stride length variability 
• COPD had increased stride 
length variability compared 
to healthy participants after 
correction for speed  
(Liu et al. 2017) 
Time in double support  
• COPD compared to healthy 
controls had increased 
double support time and 
variability  
(Nantsupawat et al. 2015) 
(Liu et al. 2017) 
Self-selected walking 
velocity 
• Gait speed reduces with 
COPD severity 
(Ilgin et al. 2011; Karpman & 
Benzo 2014) 
Discussion 
Page | 91  
 
Dynamic balance – Functional reach Test  
FR distances did not change in response to participation in either of the exertional walk tests and fell 
within expected distances, considering their demographics and the presence of COPD.  The mean of 
all FR distances measured in the present study (before and after the longest walk tests) was 30.28 cm 
(±5.6) and the mean age was 70.8 years (±8.2).  A systematic review and meta-analysis on normal 
values for the FR test gives 26.6 cm (95%CI: 25.14 to 28.06) as a reach test for community-dwelling 
older adults but found reach distance to be significantly affected by age (but not sex) (Rosa, Perracini 
& Ricci 2019).  Isles et al. (2004) gives an age-adjusted normative FR score of 34.13 cm (±0.54) for 
persons 70-79 years.  Given that a large COPD cohort study found the presence of COPD to reduce FR 
distance across all ages by 3.0 cm (95%CI: 4.2 to 1.8) (Eisner et al. 2008), the mean FR distance in the 
present study was within an expected range typical for a person 70 years old and with COPD.   
 
Using the FR test as a description of dynamic balance in the COPD cohort was a novel but feasible 
application of the test.  The FR test is a measure of self-generated perturbation (Duncan et al. 1992) 
but does not appear commonly in the COPD literature.  Despite this, a positive correlation between 
dynamic balance impairment and greater falls incidence has been established in COPD (Beauchamp, 
Brooks & Goldstein 2010; Beauchamp et al. 2009; Porto et al. 2017).   
 
The primary reason for selecting the FR test was to capture any transient change in dynamic balance 
control near peak exertion.  There is no consensus on the most sensitive balance assessment tool for 
determining risk of falling in COPD (Beauchamp 2019), however the BESTest, Mini-BESTest, Berg 
Balance Scale, and Brief-BESTest are validated identifiers of fall status in COPD (Jácome et al. 2016) 
as is the Timed Up and Go Test and Single Leg Stance Test (Beauchamp 2019; Beauchamp et al. 2009; 
Porto et al. 2017).  Neither of these tests could be utilised in the present study, as they are not able 
to capture changes in control of self-generated perturbation during a brief period while exertion 
levels are high. 
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Gait variability, exertion level, and velocity  
No clear pattern of association was identified in the present study between gait regularity and level 
of exertion at a consistent speed (6MWT) or at increasing speed (ISWT).  This finding is consistent 
with a study measuring gait parameters in healthy older adults at comfortable walking speeds during 
a maximal exhaustive walking test, and again walking for 2 kilometres (Donath et al. 2013).  In all 
three test conditions, stride frequency, stride width, double stride time and length, along with 
double stance length had a significant change in regard to test condition and post hoc analysis 
(Donath et al. 2013).  These results contrast findings from a small study of healthy people who had 
spatiotemporal gait measures, HR, and RPE recorded during six-minutes of fast walking (Nagano et 
al. 2014).  Results from this study show step length, double support time, and step width variability 
to increase with fatigue (Nagano et al. 2014).  The exact mechanism behind discrepancies in research 
investigating gait regularity response to exertion is unclear.  A study with a largely homogeneous 
population may be required to determine a clear response pattern.   
 
A unique component of the current study is the utilisation of self-paced and externally paced 
intensity as well as spatiotemporal gait measurement at different walking velocities.  The study 
design shows that self-paced walking from the 6MWT is comparable to the ISWT in its ability to 
evoke a change in exertional parameters and because the ISWT incrementally escalates in exertion 
and velocity until the point of voluntary failure several key comparisons can be made between the 
two walking tests.   
 
Firstly, the comparative study design addresses the hypothesis that exertion levels are relational to 
gait variability.  Prior to this study, gait variability is usually observed at self-selected pace and does 
not account for walking with increased effort or at a greater velocity (Lahousse et al. 2015; Yentes et 
al. 2011; Yentes et al. 2015).  Exceptions to this trend either describe gait near steady-state walking 
pace such as in a 6MWT (Beauchamp et al. 2009; Liu et al. 2017; Morlino et al. 2017) or at fixed 
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thresholds above and below self-selected walking pace (Yentes et al. 2017).  The present study found 
no degradation in gait variability despite a clear and uniform increase in effort and gait velocity.   
 
Secondly, the study findings are more clinically meaningful with the incorporation of both walking 
tests as increased or decreased velocity could been observed as a compensatory response for 
degrading dynamic balance control.  Findings form this study show that gait regularity did not change 
in response to walking velocity or effort as there was no significant change in magnitude of stance, 
stride, or swing time standard deviation means from start to end-test measures (in either walking 
tests).  This result is consistent with a study that found 30 minutes of walking at self-selected did not 
change gait variability (Da Rocha et al. 2018) and a study that found those with COPD regulated there 
self-selected walking speed to maintain a tolerable level of dyspnoea (Sanseverino et al. 2018). 
 
Lastly, the study methodology used in this study gave a comparable measure in comfortable self-
paced and pushed effortful walking.  Studies that only use self-selected pace to evoke a change in 
spatiotemporal gait parameters are likely to observe changes caused by fatigue rather than a sharp 
and pushed rise in exertion.  Findings from the present study indicate that walking velocity in those 
with COPD is modulated and limited to maintain a tolerable exertion level (or level of dyspnoea) 
rather than to sustain an adequate level of dynamic walking stability.  This supposition is based on 
the finding that there was a spike in most effort parameters including the RPE for both walking tasks 
but an apparent consistency in gait variability for both walking tests.  The clinical ramifications of this 
finding are that participation in activities such as pulmonary rehabilitation may be effective in 
increasing exertional thresholds and result in confidence to increase walking velocity. 
 
The current study has a unique finding of no change in spatiotemporal gait variability despite a 
statistically significant change in exertion in both walk tests and velocity in the ISWT.  A comparison 
study of 80 people with COPD and 38 healthy age-matched controls participated in a 6MWT with 
analysis from the Gait Real-time Analysis Interactive Lab (Liu et al. 2017).  Those with COPD (mostly 
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moderate to severe) had reduced stride and step length, as well as increased gait variability, 
compared to healthy older adults, even after correction for walking speed between groups (Liu et al. 
2017).  The study methodology differed from the present study in that it did not investigate within 
test differences of gait variability for the COPD group and gave no comparison measures of gait at 
differing walking velocities.  In contrast, Yentes et al. (2017) conducted gait analysis at three walking 
speeds: self-selected and ± 20% of self-selected speed.  Results revealed the COPD cohort to walk 
with longer step time with increased step time variability than the control group.  Yentes et al. (2017) 
also found that step width was narrower at slow speed and wider at a faster speed in COPD, and this 
trend was reversed for the control group.  Again, study methods varied from the present study in 
that it was conducted on a treadmill, the testing was at set velocities, the velocity range was limited, 
and the study focus was a comparison between disease and control groups rather than changes 
within disease group in response to exertion.   
 
Exertion Levels 
There was a marked change in exertion levels for the 6MWT, as HR, RR, and SpO2 all significantly 
changed statistically from start-test to end-test were as in the ISWT only RPE and HR changed 
statistically from start-test to end-test.  This result differs from a study that compared the 
cardiovascular (HR) and respiratory (RPE) exertional responses of the 6MWT to the ISWT and found 
no statistically significant difference between the tests (Hodgev et al. 2003).  A similar peak exercise 
response between the 6MWT and ISWT has been observed in some (Hill et al. 2012; Luxton et al. 
2008; Turner et al. 2004), but not all historic studies (Onorati et al. 2003; Singh et al. 1992).  One 
study argued the ISWT is more accurate than the 6MWT for evaluating maximal exercise tolerance in 
COPD (Onorati et al. 2003).  Despite the differing exertion profiles of the exertional walk tests, there 
was no observable pattern of change in gait variability for either test, inferring no correlation 
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Strengths of methodology 
Innovative and comprehensive measurement of exertion, gait, and balance  
The investigation is important because exertional walking tests underpin the functional assessment 
of COPD and guide pulmonary rehabilitation intensity.  This study directly compares measures of 
exertion with gait variability and balance, and exertion was measured comprehensively.  Preceding 
studies typically describe COPD gait variability in comparison to healthy controls rather than in 
response to exertion (Liu et al. 2017; Morlino et al. 2017; Yentes et al. 2017).  There are few studies 
describing normative values for gait in COPD (Zago et al. 2018) and none comparing gait variability 
directly to exertion levels despite exertional walk tests being common in clinical management.  
Several different measures of exertion were used to determine if one component of exertion had a 
larger influence on falls risk than another.  The novel use of portable pulse oximetry and 
capnography enabled study participants to walk across a gait-mat at self-selected velocity 
unimpeded at a natural walking pattern at their own velocity (unlike treadmill walking).  This study is 
the first to indicate that standing balance with self-perturbation does not deteriorate even directly 
after performing a high intensity walking task.  A possible mechanism behind this is that people can 
self-regulate their activity exertion levels to enable them to operate within a safe exercise tolerance 
boundary.  
 
Safe investigation of a falls risk factor  
Researchers in the current study safely investigated known falls risk factors to levels of exertion 
(commonly experienced during exercise testing) in a population with a demonstrated propensity to 
accidental falls and vulnerability to injury.  This research was conducted in an ethically sound and 
safe manner through close supervision of walking regularity, guarding dynamic balance control 
measurement, and constant monitoring of exertion levels to ensure they remained within safe 
parameters.  It was important to reach exertion levels near-maximum capacity to adequately prove 
or disprove the hypothesis of a correlation between exertion and walking variability and dynamic 
balance control.  The study method enabled comparison between maximum exertion to voluntary 
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failure from increasing velocity (using the ISWT) and a sub-maximal test of aerobic capacity (using 
the 6MWT).  Researchers also acted prudently by selecting exertional walk tests that had a 
demonstrated low level of adverse events (Afzal et al. 2018; Brown & Wise 2007; Jenkins & Čečins 
2011).  The 6MWT is the most commonly used measure of exercise capacity for COPD in Australia 
(Holland et al. 2014; Singh et al. 2014) and the ISWT was chosen in addition to the 6MWT because it 
is a test of maximum exercise capacity, is externally paced, and incrementally increases in intensity 
to a point at which people reach voluntary failure (Brown & Wise 2007).   
 
The use of capnography in the capture of exertion profile  
Utilising capnography to measure ETCO2 and RR during walking gave reliable and accurate data 
collection, as using pulse oximetry in the COPD cohort can present clinical difficulties.  Absent or 
false readings from pulse oximetry can occur in people with anaemia (Hakemi & Bender 2005), poor 
peripheral circulation, hypothermia, during rapid desaturation (Jensen, Onyskiw & Prasad 1998), and 
when oxygen saturation levels are low (Smith & Hofmeyr 2019).  There is reported accuracy 
limitations in pulse oximetry in anaemic people with COPD (Copur et al. 2015) and in the current 
study it was observed that SpO2 readings at times failed to register a reading.  The use of 
capnography gave a reliable measure of ETCO2, enabled continuous capture of RR, and comparison 
between two commonly used respiratory measures of exertion.   
 
Limitations of methodology 
Gait variability and dynamic balance  
There are limitations in the study from assessing gait using a gait sensor mat, and balance using the 
FR test.  Gait measurement only captures overground footfall patterns and consequently does not 
measure balance adaptations made by the hips, trunk, or upper limbs.  Technologies such as 
accelerometer‑based methods have been used since the late 1990s to map the movement of 
different body parts during locomotion (Moe-Nilssen 1998), and reference data has been established 
for healthy populations (Auvinet et al. 2002).  Depth-sensing cameras have been used to detect body 
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movement during the gait cycle.  3D motion analyses have also been utilised to measure 
spatiotemporal gait characteristics of people with COPD and identified people with COPD to have 
increased gait variability as compared to healthy age-matched individuals (Liu et al. 2017).  This 
testing method does not replicate community-dwelling or home environments and limits 
interpretation.   
 
Conditioning of study participants  
Study participants were recruited from a well-established pulmonary rehabilitation program and 
were compliant with exercise therapy.  Testing these participants may produce a possible selection 
bias and give a sample of gait variability that is more stable in response to exercise-induced exertion 
than from a broader population.  The sample population in the present study was possibly not at risk 
of exercise-induced hypercapnia either, as only one participant had a GOLD ranking of 4 (very severe) 
and the rest on average had moderate severity.  A limitation of the data is that the findings 
presented may not be true for people with more advanced disease, those who are less compliant 
with therapy, or those who are more susceptible to falls.   
 
Study size and scope  
The present study was a pilot study of 20 participants recruited from pulmonary rehabilitation with 
small and unequal numbers across each of the GOLD rankings.  There were insufficient numbers in 
the study to stratify participants by different characteristics of COPD to compare gait variability in 
different disease severity, phenotype, or fallers versus non-fallers.  The participants recruited were 
predominantly in moderate GOLD stratification and it is known that those with a mild GOLD 
stratification have better balance control, are less prone to falls than a population with a higher 
disease stratification (Horie et al. 2011) and have improved capability to perform functional tasks 
(Souza et al. 2018).  It is possible that increased gait variation may be observed in a COPD cohort that 
have more advanced COPD, are more susceptible to fatigue, and more likely to fall.  The present 
study also had insufficient numbers to stratify participants by phenotype.  One study identified that 
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people with bronchitic dominant COPD have more falls than emphysematous COPD (Voica et al. 
2016).  The primary aim of the study was to investigate if gait variability increased and if dynamic 
balance control reduced when exertion levels were high.  The study method employed did not 
adequately consider falls history or have adequate numbers to contrast COPD fallers with non-fallers.   
 
Future recommendations  
Comparison studies using different types of gait analysis  
Future research should employ new technology in gait assessment and give comparisons between 
different phenotypes of COPD and stratifications of disease progression.  Presently, there are no 
studies comparing gait variability response to exertion in COPD for fallers versus non-fallers, different 
COPD phenotypes, varying GOLD stratifications, in stable or exacerbation phase, or pre- to post-
participation in pulmonary rehabilitation.  A relatively new recommendation in COPD management is 
the early commencement of pulmonary rehabilitation following onset of an infective exacerbation 
(Puhan et al. 2016; Ryrso et al. 2018).  Gait analysis as a fall’s prediction tool could be employed to 
assess the effectiveness of such interventions.  Control group studies of this nature may elucidate 
differences in gait adaptations to exertion and be enhanced with new technologies that more 
thoroughly assess gait variability.  Three-dimensional gait analysis has been used to demonstrate 
that people with COPD have reduced stride and step lengths, along with increased gait variability, in 
comparison to healthy elderly (Liu et al. 2017).  Three-dimensional gait analysis may also assist in 
identifying common gait impairments not identifiable in gait sensor mats, such as impairments at the 
hip, knee, or ankle level.   
 
Different types of dynamic balance analysis  
In this study, dynamic balance control was measured on a flat and firm surface which may not 
replicate true to life conditions that challenge balance systems.  Alias and Justine (2014) measured 
dynamic stability in healthy adults using the Modified Clinical Test of Sensory Integration before and 
after completing a 6MWT.  Their results showed that participants had a statistically significant 
Discussion 
Page | 99  
 
reduction in balance on a soft surface but not a firm surface, and hypothesise that the change was 
due to reduced sensory integration post-exercise (Alias & Justine 2014).  It is probable that the FR 
test performed in the current study was inadequate in identifying sensory changes that occurred in 
response to elevated exertion levels.  Multiple balance measures, including BESTest, Berg balance 
scale, force plates, single leg stance and others have been used to evaluate dynamic balance in 
people with COPD (Beauchamp 2019; Beauchamp et al. 2010; Lopes et al. 2014) some of which have 
validated minimal clinically important differences for this population (Beauchamp et al. 2016).  
Future study should investigate which components of balance are most affected by exertion, and if 
the effect translates to increased falls risk. 
 
Conclusions  
Gait variability (stance time standard deviation) and dynamic balance (FR) did not deteriorate from 
either paced or un-paced exertional walking, nor did it worsen at peek exertion levels.  Gait 
variability did not deteriorate in response to increased velocity and had no clear relationship with 
measures of exertion during the walking tests.  The clinical implications of these results are that 
walking with increased exertion for functional assessment is not likely to increase gait variability, 
reduce balance control, or elevate the risk of an accidental fall from baseline levels in mild to 
moderate COPD in controlled conditions.  Measuring spatiotemporal gait variation and exertion 
concurrently was utilised as a safe and viable method for investigating falls risk in the COPD 
population.  Future research could use this same method to identify the effect exertion on gait 
variability and balance control in different subgroups of the COPD population, including fallers versus 
non-fallers, stable versus those in acute exacerbation, and pulmonary rehabilitation trained versus 
untrained.  Future investigations would require larger data sets to substantiate findings and study 
aims should focus on both identifying people at risk of falling and the ability to evaluate the 
effectiveness of interventions used to mitigate falls risk factors.    
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Changes in balance control during walking with exertion in adults with chronic obstructive 
pulmonary disease:  Protocol for a pilot study 
Dr Marie-Louise Bird1, Dr Andrew Williams1, Dr Kiran Ahuja1, David Carter1,2 
1University of Tasmania  
2Tasmanian Health Organisation  
Introduction: 
The prevalence of accidental falls in people with Chronic Obstructive Pulmonary Disease (COPD) is 
higher than the general older population.   Identified falls risks factors include poor balance 
control, increased gait variability and poor leg muscle strength from deconditioning.  Exertional 
walking tasks form the basis of physical assessments, but changes in gait regularity during exertion 
has not been well researched.  
Aim:  
This study examines changes in balance control (as measured by gait regularity and limits of 
stability) in adults with COPD during self-paced walking (6 Minute Walk Test) and externally paced 
walking with regular increases in pace (Incremental Shuttle Walking Test).  Measures of exertion 
(Modified Borg Dyspnoea Scale, SPO2 and HR) will be recorded concurrent to each walking task.  
Hypothesis:   
It is hypothesised that as people with COPD increase their level of exertion during walking tasks 
their gait regularity decreases and immediately after exertional walking their balance control is 
worse. 
Methods:  
Twenty people with COPD will be recruited from the University Exercise Clinic.  Participants with 
stable COPD will perform both a 6 Minute Walk Test and an Incremental Shuttle Test one week 
apart in a randomised order with gait regularity and oxygen saturation recorded at one-minute 
intervals.  Both the walking tasks will be performed on a GAITRite sensor mat recording walking 
pattern and gait regularity.  Before and after each walking task balance (Functional Reach) and 
perceived level of dyspnoea measures will be taken.  
Gait regularity will be analysed using linear regression modelling for within task and between task 
comparisons.  A paired T test will be used to compare functional reach prior to and after each of 
the exertional tasks 
Discussion:  
This study will provide important information on safety or falls risk during common walking tasks 
used in the COPD population. 
Appendices 
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Appendix C 
Changes in balance control during exertional walking assessments in adults with chronic 
obstructive pulmonary disease  
 
People with Chronic Obstructive Pulmonary Disease have high rates of accidental falls and poor 
balance control is a known fall risk factors in this population.  Exertional walking tasks are used in 
clinical assessments, however changes in balance control during exertional walking assessments is 
not well researched.  This study aims to assess changes in balance control after walking assessment 
and its relationship with exertion. 
 
Participants recruited from a pulmonary rehabilitation program performed two Six Minute Walk 
Tests and two Incremental Shuttle Tests one week apart in a randomised order.  Balance control was 
measured (functional reach) before and after each walk test and compared using a paired T-test.  
Concurrently measures of exertion (respiratory rate, heart rate, peripheral oxygen saturation, and 
end tidal carbon dioxide) and the Borg Scale (perceived level of exertion) were collected.  
 
Twenty people (17 female, 3 male, age 71±8 years, %FEV1 64±18%, GOLD rank 2.2±07) attended on 
two occasions. There was no significant difference between functional reach (cm) after the 6MWT 
(pre 30.0±6.3, post 30.7±5.6 p= -0.44) or IST (pre 30.9±5.9, post 29.9±5.9 p=0.31).  Exertion measures 
in table 1. 
 
Despite moderate exertion during two walking tasks, balance control as measured by functional 
reach did not change after the tests.  This has implications for clinical practice, indicating the relative 
safety of these tests for use in the COPD population. 
 
Table 1. Exertion Measures  
 Pre  
6 Min Walk 
Mean (SD) 
Post   
6 Min Walk 
Mean (SD) 
Pre  
Shuttle Walk  
Mean (SD) 
Post  
Shuttle Walk  
Mean (SD) 
RPE (10) 0.5 (0.9) 4.3 (1.6)* 0.6 (0.7) 4.6 (2.2)* 
Breaths/min 23.6 (5.3) 28.9 (6.6)* 21.9 (5.2) 32.7 (9.1) 
HR / min 92 (15) 124 (18)* 90 (15) 123 (16)* 
SpO2 /100 96 (2) 92 (5) * 96 (2) 91 (4) 
ETCO2 34 (4) 36 (4) 33 (3) 37 (6) 
 *significantly different from baseline values (p≤.05) 
 
